Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market By End User (Pharma Customers, Biotech Customers, Others); By Product (Active Pharmaceutical Ingredients, Finished Drugs); By Type of Fermentation (Aerobic, Anaerobic); By Dosage Forms (Immediate Release and Controlled Release Tablets, Multilayer Tablets, Immediate Release Capsules, Oral Multiparticulates like Beads, Pellets and Mini-tablets, Liquid and Semi-solid Filled Capsules, Fast Dispersible Tablets, Coating of Tablets, Capsules and Pellets, Micro-encapsulation Using Spray Drying, Oral Liquids and Suspensions, Liquids and Semi-solids for Topical Delivery like Creams, Ointments, Lotions and Gels, Buccal Delivery, Nasal Sprays, Dental Products, Pessaries, Others); By Clinical Phases (Phases I Trials, Phase II/ III Trials, Others); By Disease Indication (Gastrointestinal Disorders and Food Allergies – Ulcerative Colitis, Irritable Bowel Syndrome, Others, Cardiovascular Diseases, Metabolic, Autoimmune and Neurological Disorders, Diabetes, Cancer – Colon Cancer, Others, Infectious Diseases, Others); By Services (Cell Bank Preservation, Inoculum/ Seed Optimization, Media Optimization, Formulation, Fermentation Development, Harvest Development, Lyophilization Development, Analytical Method Development, Process Scale-up, Liquid Filling Services, Custom Packaging Services, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global live biotherapeutic products and microbiome contract manufacturing market is projected to grow at an estimated CAGR of 20% over the forecast period. Medical science has been making massive progress over the period of last few decades. New age medicines and treatment methods have managed to carve a niche for themselves. Biotherapeutic and microbiome-based products have proven their efficacy. As this segment is witnessing rampant advancements, the global live biotherapeutic products and microbiome contract manufacturing market will be seeing massive growth.
Product Outlook
On the basis of product, the global live biotherapeutic products and microbiome contract manufacturing market has been segmented into active pharmaceutical ingredients, and finished drugs. The active pharmaceutical ingredients segment dominates in terms of market share. New, affordable and effective drugs and medicines always are a hot-selling properties. This is the reason why segment has edge over other segments.
Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Revenue & Forecast, (US$ Million), 2022 – 2030
Type of Fermentation Outlook
On the basis of types of fermentation, the global live biotherapeutic products and microbiome contract manufacturing market has been bifurcated into aerobic and anaerobic. The anaerobic segment accounts for majority of revenue generated by this market.
Dosage Forms Outlook
The dosage forms segment of the global live biotherapeutic products and microbiome contract manufacturing market has been segregated immediate release and controlled release tablets, multilayer tablets, immediate release capsules, oral multiparticulates like beads, pellets and mini-tablets, liquid and semi-solid filled capsules, fast dispersible tablets, coating of tablets, capsules and pellets, micro-encapsulation using spray drying, oral liquids and suspensions, liquids and semi-solids for topical delivery, buccal delivery, nasal sprays, dental products, pessaries and others. The oral liquids and suspensions segment mints majority of money for this market.
Clinical Phases Outlook
The clinical phases segment of the global live biotherapeutic products and microbiome contract manufacturing market has been divided into phase I trials, phase II/III trials, and others. The phase I trials segment accounts for majority of revenue generated by this market.
Disease Indication Outlook
The disease indication segment of the global live biotherapeutic products and microbiome contract manufacturing market has been categorised into gastrointestinal disorders and food allergies, cardiovascular diseases, metabolic, autoimmune and neurological disorders, diabetes, cancer, infectious diseases and others. While the gastrointestinal disorders and food allergies segment that dominates in terms of market share has been divided into ulcerative colitis, irritable bowel syndrome and others, the cancer segment has been divided into colon cancer and others.
Services Outlook
The services segment of the global live biotherapeutic products and microbiome contract manufacturing market has been divided into cell bank preservation, inoculum/ seed optimization, media optimization, formulation, fermentation development, harvest development, lyophilisation development, analytical method development, process scale-up, liquid filling services, custom packaging services and others.
End Users Outlook
On the basis of end users, the Global live biotherapeutic products and microbiome contract manufacturing market has been divided into pharma customers, biotech customers and others. While the pharma customers buy these products for consumption, the biotech customers majorly use it for research purposes.
Region Outlook
On the basis of region, the global live biotherapeutic products and microbiome contract manufacturing market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of North America accounts for maximum amount of revenue generated by this market. Leading medical research and pharma companies are highly active in the region along with substantial amount of funding. This is why this market is flourishing in this region.
Competitive Landscape
The report provides both, qualitative and quantitative research of global live biotherapeutic products and microbiome contract manufacturing market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global live biotherapeutic products and microbiome contract manufacturing market are listed below:
- 3P Biopharmaceuticals
- Arranta Bio
- BIOSE INDUSTRIES
- BJP Industries
- Capsugel
- Cerbios-Pharma SA
- Cobra Biologics Limited
- Inpac Probiotics
- List Biological Labs, Inc
- Lonza
- Quay Pharma
- Other Market Participants
Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
By Product
- Active Pharmaceutical Ingredients
- Finished Drugs
By Type of Fermentation
- Aerobic
- Anaerobic
By Dosage Forms
- Immediate Release and Controlled Release Tablets
- Multilayer Tablets
- Immediate Release Capsules
- Oral Multiparticulates such as Beads, Pellets and Mini-tablets
- Liquid and Semi-solid Filled Capsules
- Fast Dispersible Tablets
- Coating of Tablets, Capsules and Pellets
- Micro-encapsulation Using Spray Drying
- Oral Liquids and Suspensions
- Liquids and Semi-solids for Topical Delivery such as Creams, Ointments, Lotions and Gels
- Buccal Delivery
- Nasal Sprays
- Dental Sprays
- Dental Products
- Pessaries
- Others
By Clinical Phases
- Phase I Trials
- Phase II/III trials
- Others
By Disease Indication
- Gastrointestinal Disorders and Food Allergies
- Ulcerative Colitis
- Irritable Bowel Syndrome
- Others
- Cardiovascular Diseases
- Autoimmune and Neurological Disorders
- Diabetes
- Cancer
- Colon Cancer
- Others
- Infectious Diseases
- Others
By Services
- Cell Bank Preservation
- Inoculum/ Seed Optimization
- Media Optimization
- Formulation
- Fermentation Development
- Harvest Development
- Lyophilization Development
- Analytical Method Development
- Process Scale-Up
- Liquid Filling Services
- Custom Packaging Services
- Others
By End User
- Pharma Customers
- Biotech Customers
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 - 2030
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market
6. Market
Synopsis: Live Biotherapeutic Products
and Microbiome Contract Manufacturing Market
7. Live
Biotherapeutic Products and Microbiome Contract Manufacturing Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Live Biotherapeutic Products and Microbiome
Contract Manufacturing Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market
8. Global Live
Biotherapeutic Products and Microbiome Contract Manufacturing Market Analysis
and Forecasts, 2022 - 2030
8.1. Overview
8.1.1. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn)
8.2. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
8.2.1. Pharma
Customers
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2021
8.2.1.3. Market
Forecast, 2022 - 2030
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. Biotech
Customers
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2021
8.2.2.3. Market
Forecast, 2022 - 2030
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.2.3. Others
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2021
8.2.3.3. Market
Forecast, 2022 - 2030
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2021
8.2.3.5.1.2. Market
Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2021
8.2.3.5.2.2. Market
Forecast, 2022 - 2030
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2021
8.2.3.5.3.2. Market
Forecast, 2022 - 2030
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2021
8.2.3.5.4.2. Market
Forecast, 2022 - 2030
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2021
8.2.3.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By End
User
9. Global Live
Biotherapeutic Products and Microbiome Contract Manufacturing Market Analysis
and Forecasts, 2022 - 2030
9.1. Overview
9.2. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
9.2.1. Active
Pharmaceutical Ingredients
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2021
9.2.1.3. Market
Forecast, 2022 - 2030
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Finished
Drugs
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2021
9.2.2.3. Market
Forecast, 2022 - 2030
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Product
10. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global Live
Biotherapeutic Products and Microbiome Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Type of Fermentation
10.2.1. Aerobic
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2021
10.2.1.3. Market
Forecast, 2022 - 2030
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Anaerobic
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2021
10.2.2.3. Market
Forecast, 2022 - 2030
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By Type
of Fermentation
11. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.2. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
11.2.1. Immediate
Release and Controlled Release Tablets
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2021
11.2.1.3. Market
Forecast, 2022 - 2030
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2021
11.2.1.5.1.2. Market
Forecast, 2022 - 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2021
11.2.1.5.2.2. Market
Forecast, 2022 - 2030
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2021
11.2.1.5.3.2. Market
Forecast, 2022 - 2030
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2021
11.2.1.5.4.2. Market
Forecast, 2022 - 2030
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2021
11.2.1.5.5.2. Market
Forecast, 2022 - 2030
11.2.2. Multilayer
Tablets
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2015 – 2021
11.2.2.3. Market
Forecast, 2022 - 2030
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 – 2021
11.2.2.5.1.2. Market
Forecast, 2022 - 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2021
11.2.2.5.2.2. Market
Forecast, 2022 - 2030
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2021
11.2.2.5.3.2. Market
Forecast, 2022 - 2030
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2021
11.2.2.5.4.2. Market
Forecast, 2022 - 2030
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 – 2021
11.2.2.5.5.2. Market
Forecast, 2022 - 2030
11.2.3. Immediate
Release Capsules
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2015 – 2021
11.2.3.3. Market
Forecast, 2022 - 2030
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2015 – 2021
11.2.3.5.1.2. Market
Forecast, 2022 - 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2021
11.2.3.5.2.2. Market
Forecast, 2022 - 2030
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2021
11.2.3.5.3.2. Market
Forecast, 2022 - 2030
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2021
11.2.3.5.4.2. Market
Forecast, 2022 - 2030
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2015 – 2021
11.2.3.5.5.2. Market
Forecast, 2022 - 2030
11.2.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2015 – 2021
11.2.4.3. Market
Forecast, 2022 - 2030
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2015 – 2021
11.2.4.5.1.2. Market
Forecast, 2022 - 2030
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2021
11.2.4.5.2.2. Market
Forecast, 2022 - 2030
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2021
11.2.4.5.3.2. Market
Forecast, 2022 - 2030
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2021
11.2.4.5.4.2. Market
Forecast, 2022 - 2030
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2015 – 2021
11.2.4.5.5.2. Market
Forecast, 2022 - 2030
11.2.5. Liquid
and Semi-solid Filled Capsules
11.2.5.1. Definition
11.2.5.2. Market
Estimation and Penetration, 2015 – 2021
11.2.5.3. Market
Forecast, 2022 - 2030
11.2.5.4. Compound
Annual Growth Rate (CAGR)
11.2.5.5. Regional
Bifurcation
11.2.5.5.1. North
America
11.2.5.5.1.1. Market
Estimation, 2015 – 2021
11.2.5.5.1.2. Market
Forecast, 2022 - 2030
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2015 – 2021
11.2.5.5.2.2. Market
Forecast, 2022 - 2030
11.2.5.5.3. Asia
Pacific
11.2.5.5.3.1. Market
Estimation, 2015 – 2021
11.2.5.5.3.2. Market
Forecast, 2022 - 2030
11.2.5.5.4. Middle
East and Africa
11.2.5.5.4.1. Market
Estimation, 2015 – 2021
11.2.5.5.4.2. Market
Forecast, 2022 - 2030
11.2.5.5.5. Latin
America
11.2.5.5.5.1. Market
Estimation, 2015 – 2021
11.2.5.5.5.2. Market
Forecast, 2022 - 2030
11.2.6. Fast
Dispersible Tablets
11.2.6.1. Definition
11.2.6.2. Market
Estimation and Penetration, 2015 – 2021
11.2.6.3. Market
Forecast, 2022 - 2030
11.2.6.4. Compound
Annual Growth Rate (CAGR)
11.2.6.5. Regional
Bifurcation
11.2.6.5.1. North
America
11.2.6.5.1.1. Market
Estimation, 2015 – 2021
11.2.6.5.1.2. Market
Forecast, 2022 - 2030
11.2.6.5.2. Europe
11.2.6.5.2.1. Market
Estimation, 2015 – 2021
11.2.6.5.2.2. Market
Forecast, 2022 - 2030
11.2.6.5.3. Asia
Pacific
11.2.6.5.3.1. Market
Estimation, 2015 – 2021
11.2.6.5.3.2. Market
Forecast, 2022 - 2030
11.2.6.5.4. Middle
East and Africa
11.2.6.5.4.1. Market
Estimation, 2015 – 2021
11.2.6.5.4.2. Market
Forecast, 2022 - 2030
11.2.6.5.5. Latin
America
11.2.6.5.5.1. Market
Estimation, 2015 – 2021
11.2.6.5.5.2. Market
Forecast, 2022 - 2030
11.2.7. Coating
of Tablets, Capsules and Pellets
11.2.7.1. Definition
11.2.7.2. Market
Estimation and Penetration, 2015 – 2021
11.2.7.3. Market
Forecast, 2022 - 2030
11.2.7.4. Compound
Annual Growth Rate (CAGR)
11.2.7.5. Regional
Bifurcation
11.2.7.5.1. North
America
11.2.7.5.1.1. Market
Estimation, 2015 – 2021
11.2.7.5.1.2. Market
Forecast, 2022 - 2030
11.2.7.5.2. Europe
11.2.7.5.2.1. Market
Estimation, 2015 – 2021
11.2.7.5.2.2. Market
Forecast, 2022 - 2030
11.2.7.5.3. Asia
Pacific
11.2.7.5.3.1. Market
Estimation, 2015 – 2021
11.2.7.5.3.2. Market
Forecast, 2022 - 2030
11.2.7.5.4. Middle
East and Africa
11.2.7.5.4.1. Market
Estimation, 2015 – 2021
11.2.7.5.4.2. Market
Forecast, 2022 - 2030
11.2.7.5.5. Latin
America
11.2.7.5.5.1. Market
Estimation, 2015 – 2021
11.2.7.5.5.2. Market
Forecast, 2022 - 2030
11.2.8. Micro-encapsulation
Using Spray Drying
11.2.8.1. Definition
11.2.8.2. Market
Estimation and Penetration, 2015 – 2021
11.2.8.3. Market
Forecast, 2022 - 2030
11.2.8.4. Compound
Annual Growth Rate (CAGR)
11.2.8.5. Regional
Bifurcation
11.2.8.5.1. North
America
11.2.8.5.1.1. Market
Estimation, 2015 – 2021
11.2.8.5.1.2. Market
Forecast, 2022 - 2030
11.2.8.5.2. Europe
11.2.8.5.2.1. Market
Estimation, 2015 – 2021
11.2.8.5.2.2. Market
Forecast, 2022 - 2030
11.2.8.5.3. Asia
Pacific
11.2.8.5.3.1. Market
Estimation, 2015 – 2021
11.2.8.5.3.2. Market
Forecast, 2022 - 2030
11.2.8.5.4. Middle
East and Africa
11.2.8.5.4.1. Market
Estimation, 2015 – 2021
11.2.8.5.4.2. Market
Forecast, 2022 - 2030
11.2.8.5.5. Latin
America
11.2.8.5.5.1. Market
Estimation, 2015 – 2021
11.2.8.5.5.2. Market
Forecast, 2022 - 2030
11.2.9. Oral
Liquids and Suspensions
11.2.9.1. Definition
11.2.9.2. Market
Estimation and Penetration, 2015 – 2021
11.2.9.3. Market
Forecast, 2022 - 2030
11.2.9.4. Compound
Annual Growth Rate (CAGR)
11.2.9.5. Regional
Bifurcation
11.2.9.5.1. North
America
11.2.9.5.1.1. Market
Estimation, 2015 – 2021
11.2.9.5.1.2. Market
Forecast, 2022 - 2030
11.2.9.5.2. Europe
11.2.9.5.2.1. Market
Estimation, 2015 – 2021
11.2.9.5.2.2. Market
Forecast, 2022 - 2030
11.2.9.5.3. Asia
Pacific
11.2.9.5.3.1. Market
Estimation, 2015 – 2021
11.2.9.5.3.2. Market
Forecast, 2022 - 2030
11.2.9.5.4. Middle
East and Africa
11.2.9.5.4.1. Market
Estimation, 2015 – 2021
11.2.9.5.4.2. Market
Forecast, 2022 - 2030
11.2.9.5.5. Latin
America
11.2.9.5.5.1. Market
Estimation, 2015 – 2021
11.2.9.5.5.2. Market
Forecast, 2022 - 2030
11.2.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
11.2.10.1. Definition
11.2.10.2. Market
Estimation and Penetration, 2015 – 2021
11.2.10.3. Market
Forecast, 2022 - 2030
11.2.10.4. Compound
Annual Growth Rate (CAGR)
11.2.10.5. Regional
Bifurcation
11.2.10.5.1. North
America
11.2.10.5.1.1. Market
Estimation, 2015 – 2021
11.2.10.5.1.2. Market
Forecast, 2022 - 2030
11.2.10.5.2. Europe
11.2.10.5.2.1. Market
Estimation, 2015 – 2021
11.2.10.5.2.2. Market
Forecast, 2022 - 2030
11.2.10.5.3. Asia
Pacific
11.2.10.5.3.1. Market
Estimation, 2015 – 2021
11.2.10.5.3.2. Market
Forecast, 2022 - 2030
11.2.10.5.4. Middle
East and Africa
11.2.10.5.4.1. Market
Estimation, 2015 – 2021
11.2.10.5.4.2. Market
Forecast, 2022 - 2030
11.2.10.5.5. Latin
America
11.2.10.5.5.1. Market
Estimation, 2015 – 2021
11.2.10.5.5.2. Market
Forecast, 2022 - 2030
11.2.11. Buccal
Delivery
11.2.11.1. Definition
11.2.11.2. Market
Estimation and Penetration, 2015 – 2021
11.2.11.3. Market
Forecast, 2022 - 2030
11.2.11.4. Compound
Annual Growth Rate (CAGR)
11.2.11.5. Regional
Bifurcation
11.2.11.5.1. North
America
11.2.11.5.1.1. Market
Estimation, 2015 – 2021
11.2.11.5.1.2. Market
Forecast, 2022 - 2030
11.2.11.5.2. Europe
11.2.11.5.2.1. Market
Estimation, 2015 – 2021
11.2.11.5.2.2. Market
Forecast, 2022 - 2030
11.2.11.5.3. Asia
Pacific
11.2.11.5.3.1. Market
Estimation, 2015 – 2021
11.2.11.5.3.2. Market
Forecast, 2022 - 2030
11.2.11.5.4. Middle
East and Africa
11.2.11.5.4.1. Market
Estimation, 2015 – 2021
11.2.11.5.4.2. Market
Forecast, 2022 - 2030
11.2.11.5.5. Latin
America
11.2.11.5.5.1. Market
Estimation, 2015 – 2021
11.2.11.5.5.2. Market
Forecast, 2022 - 2030
11.2.12. Nasal
Sprays
11.2.12.1. Definition
11.2.12.2. Market
Estimation and Penetration, 2015 – 2021
11.2.12.3. Market
Forecast, 2022 - 2030
11.2.12.4. Compound
Annual Growth Rate (CAGR)
11.2.12.5. Regional
Bifurcation
11.2.12.5.1. North
America
11.2.12.5.1.1. Market
Estimation, 2015 – 2021
11.2.12.5.1.2. Market
Forecast, 2022 - 2030
11.2.12.5.2. Europe
11.2.12.5.2.1. Market
Estimation, 2015 – 2021
11.2.12.5.2.2. Market
Forecast, 2022 - 2030
11.2.12.5.3. Asia
Pacific
11.2.12.5.3.1. Market
Estimation, 2015 – 2021
11.2.12.5.3.2. Market
Forecast, 2022 - 2030
11.2.12.5.4. Middle
East and Africa
11.2.12.5.4.1. Market
Estimation, 2015 – 2021
11.2.12.5.4.2. Market
Forecast, 2022 - 2030
11.2.12.5.5. Latin
America
11.2.12.5.5.1. Market
Estimation, 2015 – 2021
11.2.12.5.5.2. Market
Forecast, 2022 - 2030
11.2.13. Dental
Products
11.2.13.1. Definition
11.2.13.2. Market
Estimation and Penetration, 2015 – 2021
11.2.13.3. Market
Forecast, 2022 - 2030
11.2.13.4. Compound
Annual Growth Rate (CAGR)
11.2.13.5. Regional
Bifurcation
11.2.13.5.1. North
America
11.2.13.5.1.1. Market
Estimation, 2015 – 2021
11.2.13.5.1.2. Market
Forecast, 2022 - 2030
11.2.13.5.2. Europe
11.2.13.5.2.1. Market
Estimation, 2015 – 2021
11.2.13.5.2.2. Market
Forecast, 2022 - 2030
11.2.13.5.3. Asia
Pacific
11.2.13.5.3.1. Market
Estimation, 2015 – 2021
11.2.13.5.3.2. Market
Forecast, 2022 - 2030
11.2.13.5.4. Middle
East and Africa
11.2.13.5.4.1. Market
Estimation, 2015 – 2021
11.2.13.5.4.2. Market
Forecast, 2022 - 2030
11.2.13.5.5. Latin
America
11.2.13.5.5.1. Market
Estimation, 2015 – 2021
11.2.13.5.5.2. Market
Forecast, 2022 - 2030
11.2.14. Pessaries
11.2.14.1. Definition
11.2.14.2. Market
Estimation and Penetration, 2015 – 2021
11.2.14.3. Market
Forecast, 2022 - 2030
11.2.14.4. Compound
Annual Growth Rate (CAGR)
11.2.14.5. Regional
Bifurcation
11.2.14.5.1. North
America
11.2.14.5.1.1. Market
Estimation, 2015 – 2021
11.2.14.5.1.2. Market
Forecast, 2022 - 2030
11.2.14.5.2. Europe
11.2.14.5.2.1. Market
Estimation, 2015 – 2021
11.2.14.5.2.2. Market
Forecast, 2022 - 2030
11.2.14.5.3. Asia
Pacific
11.2.14.5.3.1. Market
Estimation, 2015 – 2021
11.2.14.5.3.2. Market
Forecast, 2022 - 2030
11.2.14.5.4. Middle
East and Africa
11.2.14.5.4.1. Market
Estimation, 2015 – 2021
11.2.14.5.4.2. Market
Forecast, 2022 - 2030
11.2.14.5.5. Latin
America
11.2.14.5.5.1. Market
Estimation, 2015 – 2021
11.2.14.5.5.2. Market
Forecast, 2022 - 2030
11.2.15. Others
11.2.15.1. Definition
11.2.15.2. Market
Estimation and Penetration, 2015 – 2021
11.2.15.3. Market
Forecast, 2022 - 2030
11.2.15.4. Compound
Annual Growth Rate (CAGR)
11.2.15.5. Regional
Bifurcation
11.2.15.5.1. North
America
11.2.15.5.1.1. Market
Estimation, 2015 – 2021
11.2.15.5.1.2. Market
Forecast, 2022 - 2030
11.2.15.5.2. Europe
11.2.15.5.2.1. Market
Estimation, 2015 – 2021
11.2.15.5.2.2. Market
Forecast, 2022 - 2030
11.2.15.5.3. Asia
Pacific
11.2.15.5.3.1. Market
Estimation, 2015 – 2021
11.2.15.5.3.2. Market
Forecast, 2022 - 2030
11.2.15.5.4. Middle
East and Africa
11.2.15.5.4.1. Market
Estimation, 2015 – 2021
11.2.15.5.4.2. Market
Forecast, 2022 - 2030
11.2.15.5.5. Latin
America
11.2.15.5.5.1. Market
Estimation, 2015 – 2021
11.2.15.5.5.2. Market
Forecast, 2022 - 2030
11.3. Key
Segment for Channeling Investments
11.3.1. By
Dosage Forms
12. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.2. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
12.2.1. Phase I
Trials
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2015 – 2021
12.2.1.3. Market
Forecast, 2022 - 2030
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 – 2021
12.2.1.5.1.2. Market
Forecast, 2022 - 2030
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2021
12.2.1.5.2.2. Market
Forecast, 2022 - 2030
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2021
12.2.1.5.3.2. Market
Forecast, 2022 - 2030
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2021
12.2.1.5.4.2. Market
Forecast, 2022 - 2030
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 – 2021
12.2.1.5.5.2. Market
Forecast, 2022 - 2030
12.2.2. Phase
II/III trials
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2015 – 2021
12.2.2.3. Market
Forecast, 2022 - 2030
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 – 2021
12.2.2.5.1.2. Market
Forecast, 2022 - 2030
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2021
12.2.2.5.2.2. Market
Forecast, 2022 - 2030
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2021
12.2.2.5.3.2. Market
Forecast, 2022 - 2030
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2021
12.2.2.5.4.2. Market
Forecast, 2022 - 2030
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 – 2021
12.2.2.5.5.2. Market
Forecast, 2022 - 2030
12.2.3. Others
12.2.3.1. Definition
12.2.3.2. Market
Estimation and Penetration, 2015 – 2021
12.2.3.3. Market
Forecast, 2022 - 2030
12.2.3.4. Compound
Annual Growth Rate (CAGR)
12.2.3.5. Regional
Bifurcation
12.2.3.5.1. North
America
12.2.3.5.1.1. Market
Estimation, 2015 – 2021
12.2.3.5.1.2. Market
Forecast, 2022 - 2030
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 – 2021
12.2.3.5.2.2. Market
Forecast, 2022 - 2030
12.2.3.5.3. Asia
Pacific
12.2.3.5.3.1. Market
Estimation, 2015 – 2021
12.2.3.5.3.2. Market
Forecast, 2022 - 2030
12.2.3.5.4. Middle
East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 – 2021
12.2.3.5.4.2. Market
Forecast, 2022 - 2030
12.2.3.5.5. Latin
America
12.2.3.5.5.1. Market
Estimation, 2015 – 2021
12.2.3.5.5.2. Market
Forecast, 2022 - 2030
12.3. Key
Segment for Channeling Investments
12.3.1. By
Clinical Phases
13. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.2. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.2.1. Gastrointestinal
Disorders and Food Allergies
13.2.1.1. Definition
13.2.1.2. Market
Estimation and Penetration, 2015 – 2021
13.2.1.3. Market
Forecast, 2022 - 2030
13.2.1.4. Compound
Annual Growth Rate (CAGR)
13.2.1.5. Regional
Bifurcation
13.2.1.5.1. North
America
13.2.1.5.1.1. Market
Estimation, 2015 – 2021
13.2.1.5.1.2. Market
Forecast, 2022 - 2030
13.2.1.5.2. Europe
13.2.1.5.2.1. Market
Estimation, 2015 – 2021
13.2.1.5.2.2. Market
Forecast, 2022 - 2030
13.2.1.5.3. Asia
Pacific
13.2.1.5.3.1. Market
Estimation, 2015 – 2021
13.2.1.5.3.2. Market
Forecast, 2022 - 2030
13.2.1.5.4. Middle
East and Africa
13.2.1.5.4.1. Market
Estimation, 2015 – 2021
13.2.1.5.4.2. Market
Forecast, 2022 - 2030
13.2.1.5.5. Latin
America
13.2.1.5.5.1. Market
Estimation, 2015 – 2021
13.2.1.5.5.2. Market
Forecast, 2022 - 2030
13.2.2. Cardiovascular
Diseases
13.2.2.1. Definition
13.2.2.2. Market
Estimation and Penetration, 2015 – 2021
13.2.2.3. Market
Forecast, 2022 - 2030
13.2.2.4. Compound
Annual Growth Rate (CAGR)
13.2.2.5. Regional
Bifurcation
13.2.2.5.1. North
America
13.2.2.5.1.1. Market
Estimation, 2015 – 2021
13.2.2.5.1.2. Market
Forecast, 2022 - 2030
13.2.2.5.2. Europe
13.2.2.5.2.1. Market
Estimation, 2015 – 2021
13.2.2.5.2.2. Market
Forecast, 2022 - 2030
13.2.2.5.3. Asia
Pacific
13.2.2.5.3.1. Market
Estimation, 2015 – 2021
13.2.2.5.3.2. Market
Forecast, 2022 - 2030
13.2.2.5.4. Middle
East and Africa
13.2.2.5.4.1. Market
Estimation, 2015 – 2021
13.2.2.5.4.2. Market
Forecast, 2022 - 2030
13.2.2.5.5. Latin
America
13.2.2.5.5.1. Market
Estimation, 2015 – 2021
13.2.2.5.5.2. Market
Forecast, 2022 - 2030
13.2.3. Metabolic
13.2.3.1. Definition
13.2.3.2. Market
Estimation and Penetration, 2015 – 2021
13.2.3.3. Market
Forecast, 2022 - 2030
13.2.3.4. Compound
Annual Growth Rate (CAGR)
13.2.3.5. Regional
Bifurcation
13.2.3.5.1. North
America
13.2.3.5.1.1. Market
Estimation, 2015 – 2021
13.2.3.5.1.2. Market
Forecast, 2022 - 2030
13.2.3.5.2. Europe
13.2.3.5.2.1. Market
Estimation, 2015 – 2021
13.2.3.5.2.2. Market
Forecast, 2022 - 2030
13.2.3.5.3. Asia
Pacific
13.2.3.5.3.1. Market
Estimation, 2015 – 2021
13.2.3.5.3.2. Market
Forecast, 2022 - 2030
13.2.3.5.4. Middle
East and Africa
13.2.3.5.4.1. Market
Estimation, 2015 – 2021
13.2.3.5.4.2. Market
Forecast, 2022 - 2030
13.2.3.5.5. Latin
America
13.2.3.5.5.1. Market
Estimation, 2015 – 2021
13.2.3.5.5.2. Market
Forecast, 2022 - 2030
13.2.4. Autoimmune
and Neurological Disorders
13.2.4.1. Definition
13.2.4.2. Market
Estimation and Penetration, 2015 – 2021
13.2.4.3. Market
Forecast, 2022 - 2030
13.2.4.4. Compound
Annual Growth Rate (CAGR)
13.2.4.5. Regional
Bifurcation
13.2.4.5.1. North
America
13.2.4.5.1.1. Market
Estimation, 2015 – 2021
13.2.4.5.1.2. Market
Forecast, 2022 - 2030
13.2.4.5.2. Europe
13.2.4.5.2.1. Market
Estimation, 2015 – 2021
13.2.4.5.2.2. Market
Forecast, 2022 - 2030
13.2.4.5.3. Asia
Pacific
13.2.4.5.3.1. Market
Estimation, 2015 – 2021
13.2.4.5.3.2. Market
Forecast, 2022 - 2030
13.2.4.5.4. Middle
East and Africa
13.2.4.5.4.1. Market
Estimation, 2015 – 2021
13.2.4.5.4.2. Market
Forecast, 2022 - 2030
13.2.4.5.5. Latin
America
13.2.4.5.5.1. Market
Estimation, 2015 – 2021
13.2.4.5.5.2. Market
Forecast, 2022 - 2030
13.2.5. Diabetes
13.2.5.1. Definition
13.2.5.2. Market
Estimation and Penetration, 2015 – 2021
13.2.5.3. Market
Forecast, 2022 - 2030
13.2.5.4. Compound
Annual Growth Rate (CAGR)
13.2.5.5. Regional
Bifurcation
13.2.5.5.1. North
America
13.2.5.5.1.1. Market
Estimation, 2015 – 2021
13.2.5.5.1.2. Market
Forecast, 2022 - 2030
13.2.5.5.2. Europe
13.2.5.5.2.1. Market
Estimation, 2015 – 2021
13.2.5.5.2.2. Market
Forecast, 2022 - 2030
13.2.5.5.3. Asia
Pacific
13.2.5.5.3.1. Market
Estimation, 2015 – 2021
13.2.5.5.3.2. Market
Forecast, 2022 - 2030
13.2.5.5.4. Middle
East and Africa
13.2.5.5.4.1. Market
Estimation, 2015 – 2021
13.2.5.5.4.2. Market
Forecast, 2022 - 2030
13.2.5.5.5. Latin
America
13.2.5.5.5.1. Market
Estimation, 2015 – 2021
13.2.5.5.5.2. Market
Forecast, 2022 - 2030
13.2.6. Cancer
13.2.6.1. Definition
13.2.6.2. Market
Estimation and Penetration, 2015 – 2021
13.2.6.3. Market
Forecast, 2022 - 2030
13.2.6.4. Compound
Annual Growth Rate (CAGR)
13.2.6.5. Regional
Bifurcation
13.2.6.5.1. North
America
13.2.6.5.1.1. Market
Estimation, 2015 – 2021
13.2.6.5.1.2. Market
Forecast, 2022 - 2030
13.2.6.5.2. Europe
13.2.6.5.2.1. Market
Estimation, 2015 – 2021
13.2.6.5.2.2. Market
Forecast, 2022 - 2030
13.2.6.5.3. Asia
Pacific
13.2.6.5.3.1. Market
Estimation, 2015 – 2021
13.2.6.5.3.2. Market
Forecast, 2022 - 2030
13.2.6.5.4. Middle
East and Africa
13.2.6.5.4.1. Market
Estimation, 2015 – 2021
13.2.6.5.4.2. Market
Forecast, 2022 - 2030
13.2.6.5.5. Latin
America
13.2.6.5.5.1. Market
Estimation, 2015 – 2021
13.2.6.5.5.2. Market
Forecast, 2022 - 2030
13.2.7. Infectious
Diseases
13.2.7.1. Definition
13.2.7.2. Market
Estimation and Penetration, 2015 – 2021
13.2.7.3. Market
Forecast, 2022 - 2030
13.2.7.4. Compound
Annual Growth Rate (CAGR)
13.2.7.5. Regional
Bifurcation
13.2.7.5.1. North
America
13.2.7.5.1.1. Market
Estimation, 2015 – 2021
13.2.7.5.1.2. Market
Forecast, 2022 - 2030
13.2.7.5.2. Europe
13.2.7.5.2.1. Market
Estimation, 2015 – 2021
13.2.7.5.2.2. Market
Forecast, 2022 - 2030
13.2.7.5.3. Asia
Pacific
13.2.7.5.3.1. Market
Estimation, 2015 – 2021
13.2.7.5.3.2. Market
Forecast, 2022 - 2030
13.2.7.5.4. Middle
East and Africa
13.2.7.5.4.1. Market
Estimation, 2015 – 2021
13.2.7.5.4.2. Market
Forecast, 2022 - 2030
13.2.7.5.5. Latin
America
13.2.7.5.5.1. Market
Estimation, 2015 – 2021
13.2.7.5.5.2. Market
Forecast, 2022 - 2030
13.2.8. Others
13.2.8.1. Definition
13.2.8.2. Market
Estimation and Penetration, 2015 – 2021
13.2.8.3. Market
Forecast, 2022 - 2030
13.2.8.4. Compound
Annual Growth Rate (CAGR)
13.2.8.5. Regional
Bifurcation
13.2.8.5.1. North
America
13.2.8.5.1.1. Market
Estimation, 2015 – 2021
13.2.8.5.1.2. Market
Forecast, 2022 - 2030
13.2.8.5.2. Europe
13.2.8.5.2.1. Market
Estimation, 2015 – 2021
13.2.8.5.2.2. Market
Forecast, 2022 - 2030
13.2.8.5.3. Asia
Pacific
13.2.8.5.3.1. Market
Estimation, 2015 – 2021
13.2.8.5.3.2. Market
Forecast, 2022 - 2030
13.2.8.5.4. Middle
East and Africa
13.2.8.5.4.1. Market
Estimation, 2015 – 2021
13.2.8.5.4.2. Market
Forecast, 2022 - 2030
13.2.8.5.5. Latin
America
13.2.8.5.5.1. Market
Estimation, 2015 – 2021
13.2.8.5.5.2. Market
Forecast, 2022 - 2030
13.3. Key
Segment for Channeling Investments
13.3.1. By
Disease Indication
14. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.2. Global
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
14.2.1. Cell
Bank Preservation
14.2.1.1. Definition
14.2.1.2. Market
Estimation and Penetration, 2015 – 2021
14.2.1.3. Market
Forecast, 2022 - 2030
14.2.1.4. Compound
Annual Growth Rate (CAGR)
14.2.1.5. Regional
Bifurcation
14.2.1.5.1. North
America
14.2.1.5.1.1. Market
Estimation, 2015 – 2021
14.2.1.5.1.2. Market
Forecast, 2022 - 2030
14.2.1.5.2. Europe
14.2.1.5.2.1. Market
Estimation, 2015 – 2021
14.2.1.5.2.2. Market
Forecast, 2022 - 2030
14.2.1.5.3. Asia
Pacific
14.2.1.5.3.1. Market
Estimation, 2015 – 2021
14.2.1.5.3.2. Market
Forecast, 2022 - 2030
14.2.1.5.4. Middle
East and Africa
14.2.1.5.4.1. Market
Estimation, 2015 – 2021
14.2.1.5.4.2. Market
Forecast, 2022 - 2030
14.2.1.5.5. Latin
America
14.2.1.5.5.1. Market
Estimation, 2015 – 2021
14.2.1.5.5.2. Market
Forecast, 2022 - 2030
14.2.2. Inoculum/Seed
Optimization
14.2.2.1. Definition
14.2.2.2. Market
Estimation and Penetration, 2015 – 2021
14.2.2.3. Market
Forecast, 2022 - 2030
14.2.2.4. Compound
Annual Growth Rate (CAGR)
14.2.2.5. Regional
Bifurcation
14.2.2.5.1. North
America
14.2.2.5.1.1. Market
Estimation, 2015 – 2021
14.2.2.5.1.2. Market
Forecast, 2022 - 2030
14.2.2.5.2. Europe
14.2.2.5.2.1. Market
Estimation, 2015 – 2021
14.2.2.5.2.2. Market
Forecast, 2022 - 2030
14.2.2.5.3. Asia
Pacific
14.2.2.5.3.1. Market
Estimation, 2015 – 2021
14.2.2.5.3.2. Market
Forecast, 2022 - 2030
14.2.2.5.4. Middle
East and Africa
14.2.2.5.4.1. Market
Estimation, 2015 – 2021
14.2.2.5.4.2. Market
Forecast, 2022 - 2030
14.2.2.5.5. Latin
America
14.2.2.5.5.1. Market
Estimation, 2015 – 2021
14.2.2.5.5.2. Market
Forecast, 2022 - 2030
14.2.3. Media
Optimization
14.2.3.1. Definition
14.2.3.2. Market
Estimation and Penetration, 2015 – 2021
14.2.3.3. Market
Forecast, 2022 - 2030
14.2.3.4. Compound
Annual Growth Rate (CAGR)
14.2.3.5. Regional
Bifurcation
14.2.3.5.1. North
America
14.2.3.5.1.1. Market
Estimation, 2015 – 2021
14.2.3.5.1.2. Market
Forecast, 2022 - 2030
14.2.3.5.2. Europe
14.2.3.5.2.1. Market
Estimation, 2015 – 2021
14.2.3.5.2.2. Market
Forecast, 2022 - 2030
14.2.3.5.3. Asia
Pacific
14.2.3.5.3.1. Market
Estimation, 2015 – 2021
14.2.3.5.3.2. Market
Forecast, 2022 - 2030
14.2.3.5.4. Middle
East and Africa
14.2.3.5.4.1. Market
Estimation, 2015 – 2021
14.2.3.5.4.2. Market
Forecast, 2022 - 2030
14.2.3.5.5. Latin
America
14.2.3.5.5.1. Market
Estimation, 2015 – 2021
14.2.3.5.5.2. Market
Forecast, 2022 - 2030
14.2.4. Formulation
14.2.4.1. Definition
14.2.4.2. Market
Estimation and Penetration, 2015 – 2021
14.2.4.3. Market
Forecast, 2022 - 2030
14.2.4.4. Compound
Annual Growth Rate (CAGR)
14.2.4.5. Regional
Bifurcation
14.2.4.5.1. North
America
14.2.4.5.1.1. Market
Estimation, 2015 – 2021
14.2.4.5.1.2. Market
Forecast, 2022 - 2030
14.2.4.5.2. Europe
14.2.4.5.2.1. Market
Estimation, 2015 – 2021
14.2.4.5.2.2. Market
Forecast, 2022 - 2030
14.2.4.5.3. Asia
Pacific
14.2.4.5.3.1. Market
Estimation, 2015 – 2021
14.2.4.5.3.2. Market
Forecast, 2022 - 2030
14.2.4.5.4. Middle
East and Africa
14.2.4.5.4.1. Market
Estimation, 2015 – 2021
14.2.4.5.4.2. Market
Forecast, 2022 - 2030
14.2.4.5.5. Latin
America
14.2.4.5.5.1. Market
Estimation, 2015 – 2021
14.2.4.5.5.2. Market
Forecast, 2022 - 2030
14.2.5. Fermentation
Development
14.2.5.1. Definition
14.2.5.2. Market
Estimation and Penetration, 2015 – 2021
14.2.5.3. Market
Forecast, 2022 - 2030
14.2.5.4. Compound
Annual Growth Rate (CAGR)
14.2.5.5. Regional
Bifurcation
14.2.5.5.1. North
America
14.2.5.5.1.1. Market
Estimation, 2015 – 2021
14.2.5.5.1.2. Market
Forecast, 2022 - 2030
14.2.5.5.2. Europe
14.2.5.5.2.1. Market
Estimation, 2015 – 2021
14.2.5.5.2.2. Market
Forecast, 2022 - 2030
14.2.5.5.3. Asia
Pacific
14.2.5.5.3.1. Market
Estimation, 2015 – 2021
14.2.5.5.3.2. Market
Forecast, 2022 - 2030
14.2.5.5.4. Middle
East and Africa
14.2.5.5.4.1. Market
Estimation, 2015 – 2021
14.2.5.5.4.2. Market
Forecast, 2022 - 2030
14.2.5.5.5. Latin
America
14.2.5.5.5.1. Market
Estimation, 2015 – 2021
14.2.5.5.5.2. Market
Forecast, 2022 - 2030
14.2.6. Harvest
Development
14.2.6.1. Definition
14.2.6.2. Market
Estimation and Penetration, 2015 – 2021
14.2.6.3. Market
Forecast, 2022 - 2030
14.2.6.4. Compound
Annual Growth Rate (CAGR)
14.2.6.5. Regional
Bifurcation
14.2.6.5.1. North
America
14.2.6.5.1.1. Market
Estimation, 2015 – 2021
14.2.6.5.1.2. Market
Forecast, 2022 - 2030
14.2.6.5.2. Europe
14.2.6.5.2.1. Market
Estimation, 2015 – 2021
14.2.6.5.2.2. Market
Forecast, 2022 - 2030
14.2.6.5.3. Asia
Pacific
14.2.6.5.3.1. Market
Estimation, 2015 – 2021
14.2.6.5.3.2. Market
Forecast, 2022 - 2030
14.2.6.5.4. Middle
East and Africa
14.2.6.5.4.1. Market
Estimation, 2015 – 2021
14.2.6.5.4.2. Market
Forecast, 2022 - 2030
14.2.6.5.5. Latin
America
14.2.6.5.5.1. Market
Estimation, 2015 – 2021
14.2.6.5.5.2. Market
Forecast, 2022 - 2030
14.2.7. Lyophilization
Development
14.2.7.1. Definition
14.2.7.2. Market
Estimation and Penetration, 2015 – 2021
14.2.7.3. Market
Forecast, 2022 - 2030
14.2.7.4. Compound
Annual Growth Rate (CAGR)
14.2.7.5. Regional
Bifurcation
14.2.7.5.1. North
America
14.2.7.5.1.1. Market
Estimation, 2015 – 2021
14.2.7.5.1.2. Market
Forecast, 2022 - 2030
14.2.7.5.2. Europe
14.2.7.5.2.1. Market
Estimation, 2015 – 2021
14.2.7.5.2.2. Market
Forecast, 2022 - 2030
14.2.7.5.3. Asia
Pacific
14.2.7.5.3.1. Market
Estimation, 2015 – 2021
14.2.7.5.3.2. Market
Forecast, 2022 - 2030
14.2.7.5.4. Middle
East and Africa
14.2.7.5.4.1. Market
Estimation, 2015 – 2021
14.2.7.5.4.2. Market
Forecast, 2022 - 2030
14.2.7.5.5. Latin
America
14.2.7.5.5.1. Market
Estimation, 2015 – 2021
14.2.7.5.5.2. Market
Forecast, 2022 - 2030
14.2.8. Analytical
Method Development
14.2.8.1. Definition
14.2.8.2. Market
Estimation and Penetration, 2015 – 2021
14.2.8.3. Market
Forecast, 2022 - 2030
14.2.8.4. Compound
Annual Growth Rate (CAGR)
14.2.8.5. Regional
Bifurcation
14.2.8.5.1. North
America
14.2.8.5.1.1. Market
Estimation, 2015 – 2021
14.2.8.5.1.2. Market
Forecast, 2022 - 2030
14.2.8.5.2. Europe
14.2.8.5.2.1. Market
Estimation, 2015 – 2021
14.2.8.5.2.2. Market
Forecast, 2022 - 2030
14.2.8.5.3. Asia
Pacific
14.2.8.5.3.1. Market
Estimation, 2015 – 2021
14.2.8.5.3.2. Market
Forecast, 2022 - 2030
14.2.8.5.4. Middle
East and Africa
14.2.8.5.4.1. Market
Estimation, 2015 – 2021
14.2.8.5.4.2. Market
Forecast, 2022 - 2030
14.2.8.5.5. Latin
America
14.2.8.5.5.1. Market
Estimation, 2015 – 2021
14.2.8.5.5.2. Market
Forecast, 2022 - 2030
14.2.9. Process
Scale-Up
14.2.9.1. Definition
14.2.9.2. Market
Estimation and Penetration, 2015 – 2021
14.2.9.3. Market
Forecast, 2022 - 2030
14.2.9.4. Compound
Annual Growth Rate (CAGR)
14.2.9.5. Regional
Bifurcation
14.2.9.5.1. North
America
14.2.9.5.1.1. Market
Estimation, 2015 – 2021
14.2.9.5.1.2. Market
Forecast, 2022 - 2030
14.2.9.5.2. Europe
14.2.9.5.2.1. Market
Estimation, 2015 – 2021
14.2.9.5.2.2. Market
Forecast, 2022 - 2030
14.2.9.5.3. Asia
Pacific
14.2.9.5.3.1. Market
Estimation, 2015 – 2021
14.2.9.5.3.2. Market
Forecast, 2022 - 2030
14.2.9.5.4. Middle
East and Africa
14.2.9.5.4.1. Market
Estimation, 2015 – 2021
14.2.9.5.4.2. Market
Forecast, 2022 - 2030
14.2.9.5.5. Latin
America
14.2.9.5.5.1. Market
Estimation, 2015 – 2021
14.2.9.5.5.2. Market
Forecast, 2022 - 2030
14.2.10. Liquid
Filling Services
14.2.10.1. Definition
14.2.10.2. Market
Estimation and Penetration, 2015 – 2021
14.2.10.3. Market
Forecast, 2022 - 2030
14.2.10.4. Compound
Annual Growth Rate (CAGR)
14.2.10.5. Regional
Bifurcation
14.2.10.5.1. North
America
14.2.10.5.1.1. Market
Estimation, 2015 – 2021
14.2.10.5.1.2. Market
Forecast, 2022 - 2030
14.2.10.5.2. Europe
14.2.10.5.2.1. Market
Estimation, 2015 – 2021
14.2.10.5.2.2. Market
Forecast, 2022 - 2030
14.2.10.5.3. Asia
Pacific
14.2.10.5.3.1. Market
Estimation, 2015 – 2021
14.2.10.5.3.2. Market
Forecast, 2022 - 2030
14.2.10.5.4. Middle
East and Africa
14.2.10.5.4.1. Market
Estimation, 2015 – 2021
14.2.10.5.4.2. Market
Forecast, 2022 - 2030
14.2.10.5.5. Latin
America
14.2.10.5.5.1. Market
Estimation, 2015 – 2021
14.2.10.5.5.2. Market
Forecast, 2022 - 2030
14.2.11. Custom
Packaging Services
14.2.11.1. Definition
14.2.11.2. Market
Estimation and Penetration, 2015 – 2021
14.2.11.3. Market
Forecast, 2022 - 2030
14.2.11.4. Compound
Annual Growth Rate (CAGR)
14.2.11.5. Regional
Bifurcation
14.2.11.5.1. North
America
14.2.11.5.1.1. Market
Estimation, 2015 – 2021
14.2.11.5.1.2. Market
Forecast, 2022 - 2030
14.2.11.5.2. Europe
14.2.11.5.2.1. Market
Estimation, 2015 – 2021
14.2.11.5.2.2. Market
Forecast, 2022 - 2030
14.2.11.5.3. Asia
Pacific
14.2.11.5.3.1. Market
Estimation, 2015 – 2021
14.2.11.5.3.2. Market
Forecast, 2022 - 2030
14.2.11.5.4. Middle
East and Africa
14.2.11.5.4.1. Market
Estimation, 2015 – 2021
14.2.11.5.4.2. Market
Forecast, 2022 - 2030
14.2.11.5.5. Latin
America
14.2.11.5.5.1. Market
Estimation, 2015 – 2021
14.2.11.5.5.2. Market
Forecast, 2022 - 2030
14.2.12. Others
14.2.12.1. Definition
14.2.12.2. Market
Estimation and Penetration, 2015 – 2021
14.2.12.3. Market
Forecast, 2022 - 2030
14.2.12.4. Compound
Annual Growth Rate (CAGR)
14.2.12.5. Regional
Bifurcation
14.2.12.5.1. North
America
14.2.12.5.1.1. Market
Estimation, 2015 – 2021
14.2.12.5.1.2. Market
Forecast, 2022 - 2030
14.2.12.5.2. Europe
14.2.12.5.2.1. Market
Estimation, 2015 – 2021
14.2.12.5.2.2. Market
Forecast, 2022 - 2030
14.2.12.5.3. Asia
Pacific
14.2.12.5.3.1. Market
Estimation, 2015 – 2021
14.2.12.5.3.2. Market
Forecast, 2022 - 2030
14.2.12.5.4. Middle
East and Africa
14.2.12.5.4.1. Market
Estimation, 2015 – 2021
14.2.12.5.4.2. Market
Forecast, 2022 - 2030
14.2.12.5.5. Latin
America
14.2.12.5.5.1. Market
Estimation, 2015 – 2021
14.2.12.5.5.2. Market
Forecast, 2022 - 2030
14.3. Key
Segment for Channeling Investments
14.3.1. By
Services
15. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn)
15.2. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
15.2.1. Pharma
Customers
15.2.2. Biotech
Customers
15.2.3. Others
15.3. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
15.3.1. Active
Pharmaceutical Ingredients
15.3.2. Finished
Drugs
15.4. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
15.4.1. Aerobic
15.4.2. Anaerobic
15.5. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
15.5.1. Immediate
Release and Controlled Release Tablets
15.5.2. Multilayer
Tablets
15.5.3. Immediate
Release Capsules
15.5.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
15.5.5. Liquid
and Semi-solid Filled Capsules
15.5.6. Fast
Dispersible Tablets
15.5.7. Coating
of Tablets, Capsules and Pellets
15.5.8. Micro-encapsulation
Using Spray Drying
15.5.9. Oral
Liquids and Suspensions
15.5.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
15.5.11. Buccal
Delivery
15.5.12. Nasal
Sprays
15.5.13. Dental
Products
15.5.14. Pessaries
15.5.15. Others
15.6. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.6.1. Phase I
Trials
15.6.2. Phase
II/III trials
15.6.3. Others
15.7. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.7.1. Gastrointestinal
Disorders and Food Allergies
15.7.2. Cardiovascular
Diseases
15.7.3. Metabolic
15.7.4. Autoimmune
and Neurological Disorders
15.7.5. Diabetes
15.7.6. Cancer
15.7.7. Infectious
Diseases
15.7.8. Others
15.8. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
15.8.1. Cell
Bank Preservation
15.8.2. Inoculum/Seed
Optimization
15.8.3. Media
Optimization
15.8.4. Formulation
15.8.5. Fermentation
Development
15.8.6. Harvest
Development
15.8.7. Lyophilization
Development
15.8.8. Analytical
Method Development
15.8.9. Process
Scale-Up
15.8.10. Liquid
Filling Services
15.8.11. Custom
Packaging Services
15.8.12. Others
15.9. North
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Country
15.9.1. U.S
15.9.1.1. U.S
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
15.9.1.1.1. Pharma
Customers
15.9.1.1.2. Biotech
Customers
15.9.1.1.3. Others
15.9.1.2. U.S
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
15.9.1.2.1. Active
Pharmaceutical Ingredients
15.9.1.2.2. Finished
Drugs
15.9.1.3. U.S
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
15.9.1.3.1. Aerobic
15.9.1.3.2. Anaerobic
15.9.1.4. U.S
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
15.9.1.4.1. Immediate
Release and Controlled Release Tablets
15.9.1.4.2. Multilayer
Tablets
15.9.1.4.3. Immediate
Release Capsules
15.9.1.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
15.9.1.4.5. Liquid
and Semi-solid Filled Capsules
15.9.1.4.6. Fast
Dispersible Tablets
15.9.1.4.7. Coating
of Tablets, Capsules and Pellets
15.9.1.4.8. Micro-encapsulation
Using Spray Drying
15.9.1.4.9. Oral
Liquids and Suspensions
15.9.1.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
15.9.1.4.11. Buccal
Delivery
15.9.1.4.12. Nasal
Sprays
15.9.1.4.13. Dental
Products
15.9.1.4.14. Pessaries
15.9.1.4.15. Others
15.9.1.5. U.S
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.9.1.5.1. Phase
I Trials
15.9.1.5.2. Phase
II/III trials
15.9.1.5.3. Others
15.9.1.6. U.S
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
15.9.1.6.1. Gastrointestinal
Disorders and Food Allergies
15.9.1.6.2. Cardiovascular
Diseases
15.9.1.6.3. Metabolic
15.9.1.6.4. Autoimmune
and Neurological Disorders
15.9.1.6.5. Diabetes
15.9.1.6.6. Cancer
15.9.1.6.7. Infectious
Diseases
15.9.1.6.8. Others
15.9.1.7. U.S
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
15.9.1.7.1. Cell
Bank Preservation
15.9.1.7.2. Inoculum/Seed
Optimization
15.9.1.7.3. Media
Optimization
15.9.1.7.4. Formulation
15.9.1.7.5. Fermentation
Development
15.9.1.7.6. Harvest
Development
15.9.1.7.7. Lyophilization
Development
15.9.1.7.8. Analytical
Method Development
15.9.1.7.9. Process
Scale-Up
15.9.1.7.10. Liquid
Filling Services
15.9.1.7.11. Custom
Packaging Services
15.9.1.7.12. Others
15.9.2. Canada
15.9.2.1. Canada
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
15.9.2.1.1. Pharma
Customers
15.9.2.1.2. Biotech
Customers
15.9.2.1.3. Others
15.9.2.2. Canada
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
15.9.2.2.1. Active
Pharmaceutical Ingredients
15.9.2.2.2. Finished
Drugs
15.9.2.3. Canada
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
15.9.2.3.1. Aerobic
15.9.2.3.2. Anaerobic
15.9.2.4. Canada
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
15.9.2.4.1. Immediate
Release and Controlled Release Tablets
15.9.2.4.2. Multilayer
Tablets
15.9.2.4.3. Immediate
Release Capsules
15.9.2.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
15.9.2.4.5. Liquid
and Semi-solid Filled Capsules
15.9.2.4.6. Fast
Dispersible Tablets
15.9.2.4.7. Coating
of Tablets, Capsules and Pellets
15.9.2.4.8. Micro-encapsulation
Using Spray Drying
15.9.2.4.9. Oral
Liquids and Suspensions
15.9.2.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
15.9.2.4.11. Buccal
Delivery
15.9.2.4.12. Nasal
Sprays
15.9.2.4.13. Dental
Products
15.9.2.4.14. Pessaries
15.9.2.4.15. Others
15.9.2.5. Canada
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.9.2.5.1. Phase
I Trials
15.9.2.5.2. Phase
II/III trials
15.9.2.5.3. Others
15.9.2.6. Canada
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
15.9.2.6.1. Gastrointestinal
Disorders and Food Allergies
15.9.2.6.2. Cardiovascular
Diseases
15.9.2.6.3. Metabolic
15.9.2.6.4. Autoimmune
and Neurological Disorders
15.9.2.6.5. Diabetes
15.9.2.6.6. Cancer
15.9.2.6.7. Infectious
Diseases
15.9.2.6.8. Others
15.9.2.7. Canada
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
15.9.2.7.1. Cell
Bank Preservation
15.9.2.7.2. Inoculum/Seed
Optimization
15.9.2.7.3. Media
Optimization
15.9.2.7.4. Formulation
15.9.2.7.5. Fermentation
Development
15.9.2.7.6. Harvest
Development
15.9.2.7.7. Lyophilization
Development
15.9.2.7.8. Analytical
Method Development
15.9.2.7.9. Process
Scale-Up
15.9.2.7.10. Liquid
Filling Services
15.9.2.7.11. Custom
Packaging Services
15.9.2.7.12. Others
15.9.3. Mexico
15.9.3.1. Mexico
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
15.9.3.1.1. Pharma
Customers
15.9.3.1.2. Biotech
Customers
15.9.3.1.3. Others
15.9.3.2. Mexico
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
15.9.3.2.1. Active
Pharmaceutical Ingredients
15.9.3.2.2. Finished
Drugs
15.9.3.3. Mexico
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
15.9.3.3.1. Aerobic
15.9.3.3.2. Anaerobic
15.9.3.4. Mexico
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
15.9.3.4.1. Immediate
Release and Controlled Release Tablets
15.9.3.4.2. Multilayer
Tablets
15.9.3.4.3. Immediate
Release Capsules
15.9.3.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
15.9.3.4.5. Liquid
and Semi-solid Filled Capsules
15.9.3.4.6. Fast
Dispersible Tablets
15.9.3.4.7. Coating
of Tablets, Capsules and Pellets
15.9.3.4.8. Micro-encapsulation
Using Spray Drying
15.9.3.4.9. Oral
Liquids and Suspensions
15.9.3.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
15.9.3.4.11. Buccal
Delivery
15.9.3.4.12. Nasal
Sprays
15.9.3.4.13. Dental
Products
15.9.3.4.14. Pessaries
15.9.3.4.15. Others
15.9.3.5. Mexico
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.9.3.5.1. Phase
I Trials
15.9.3.5.2. Phase
II/III trials
15.9.3.5.3. Others
15.9.3.6. Mexico
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
15.9.3.6.1. Gastrointestinal
Disorders and Food Allergies
15.9.3.6.2. Cardiovascular
Diseases
15.9.3.6.3. Metabolic
15.9.3.6.4. Autoimmune
and Neurological Disorders
15.9.3.6.5. Diabetes
15.9.3.6.6. Cancer
15.9.3.6.7. Infectious
Diseases
15.9.3.6.8. Others
15.9.3.7. Mexico
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
15.9.3.7.1. Cell
Bank Preservation
15.9.3.7.2. Inoculum/Seed
Optimization
15.9.3.7.3. Media
Optimization
15.9.3.7.4. Formulation
15.9.3.7.5. Fermentation
Development
15.9.3.7.6. Harvest
Development
15.9.3.7.7. Lyophilization
Development
15.9.3.7.8. Analytical
Method Development
15.9.3.7.9. Process
Scale-Up
15.9.3.7.10. Liquid
Filling Services
15.9.3.7.11. Custom
Packaging Services
15.9.3.7.12. Others
15.9.4. Rest of
North America
15.9.4.1. Rest
of North America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By End User
15.9.4.1.1. Pharma
Customers
15.9.4.1.2. Biotech
Customers
15.9.4.1.3. Others
15.9.4.2. Rest
of North America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Product
15.9.4.2.1. Active
Pharmaceutical Ingredients
15.9.4.2.2. Finished
Drugs
15.9.4.3. Rest
of North America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
15.9.4.3.1. Aerobic
15.9.4.3.2. Anaerobic
15.9.4.4. Rest
of North America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
15.9.4.4.1. Immediate
Release and Controlled Release Tablets
15.9.4.4.2. Multilayer
Tablets
15.9.4.4.3. Immediate
Release Capsules
15.9.4.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
15.9.4.4.5. Liquid
and Semi-solid Filled Capsules
15.9.4.4.6. Fast
Dispersible Tablets
15.9.4.4.7. Coating
of Tablets, Capsules and Pellets
15.9.4.4.8. Micro-encapsulation
Using Spray Drying
15.9.4.4.9. Oral
Liquids and Suspensions
15.9.4.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
15.9.4.4.11. Buccal
Delivery
15.9.4.4.12. Nasal
Sprays
15.9.4.4.13. Dental
Products
15.9.4.4.14. Pessaries
15.9.4.4.15. Others
15.9.4.5. Rest
of North America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.9.4.5.1. Phase
I Trials
15.9.4.5.2. Phase
II/III trials
15.9.4.5.3. Others
15.9.4.6. Rest
of North America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.9.4.6.1. Gastrointestinal
Disorders and Food Allergies
15.9.4.6.2. Cardiovascular
Diseases
15.9.4.6.3. Metabolic
15.9.4.6.4. Autoimmune
and Neurological Disorders
15.9.4.6.5. Diabetes
15.9.4.6.6. Cancer
15.9.4.6.7. Infectious
Diseases
15.9.4.6.8. Others
15.9.4.7. Rest
of North America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Services
15.9.4.7.1. Cell
Bank Preservation
15.9.4.7.2. Inoculum/Seed
Optimization
15.9.4.7.3. Media
Optimization
15.9.4.7.4. Formulation
15.9.4.7.5. Fermentation
Development
15.9.4.7.6. Harvest
Development
15.9.4.7.7. Lyophilization
Development
15.9.4.7.8. Analytical
Method Development
15.9.4.7.9. Process
Scale-Up
15.9.4.7.10. Liquid
Filling Services
15.9.4.7.11. Custom
Packaging Services
15.9.4.7.12. Others
15.10. Key
Segment for Channeling Investments
15.10.1. By
Country
15.10.2. By End
User
15.10.3. By
Product
15.10.4. By
Type of Fermentation
15.10.5. By
Dosage Forms
15.10.6. By
Clinical Phases
15.10.7. By
Disease Indication
15.10.8. By
Services
16. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn)
16.2. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
16.2.1. Pharma
Customers
16.2.2. Biotech
Customers
16.2.3. Others
16.3. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
16.3.1. Active
Pharmaceutical Ingredients
16.3.2. Finished
Drugs
16.4. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.4.1. Aerobic
16.4.2. Anaerobic
16.5. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.5.1. Immediate
Release and Controlled Release Tablets
16.5.2. Multilayer
Tablets
16.5.3. Immediate
Release Capsules
16.5.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.5.5. Liquid
and Semi-solid Filled Capsules
16.5.6. Fast
Dispersible Tablets
16.5.7. Coating
of Tablets, Capsules and Pellets
16.5.8. Micro-encapsulation
Using Spray Drying
16.5.9. Oral
Liquids and Suspensions
16.5.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.5.11. Buccal
Delivery
16.5.12. Nasal
Sprays
16.5.13. Dental
Products
16.5.14. Pessaries
16.5.15. Others
16.6. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.6.1. Phase I
Trials
16.6.2. Phase
II/III trials
16.6.3. Others
16.7. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
16.7.1. Gastrointestinal
Disorders and Food Allergies
16.7.2. Cardiovascular
Diseases
16.7.3. Metabolic
16.7.4. Autoimmune
and Neurological Disorders
16.7.5. Diabetes
16.7.6. Cancer
16.7.7. Infectious
Diseases
16.7.8. Others
16.8. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
16.8.1. Cell
Bank Preservation
16.8.2. Inoculum/Seed
Optimization
16.8.3. Media
Optimization
16.8.4. Formulation
16.8.5. Fermentation
Development
16.8.6. Harvest
Development
16.8.7. Lyophilization
Development
16.8.8. Analytical
Method Development
16.8.9. Process
Scale-Up
16.8.10. Liquid
Filling Services
16.8.11. Custom
Packaging Services
16.8.12. Others
16.9. Europe
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Country
16.9.1. France
16.9.1.1. France
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
16.9.1.1.1. Pharma
Customers
16.9.1.1.2. Biotech
Customers
16.9.1.1.3. Others
16.9.1.2. France
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
16.9.1.2.1. Active
Pharmaceutical Ingredients
16.9.1.2.2. Finished
Drugs
16.9.1.3. France
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.1.3.1. Aerobic
16.9.1.3.2. Anaerobic
16.9.1.4. France
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.1.4.1. Immediate
Release and Controlled Release Tablets
16.9.1.4.2. Multilayer
Tablets
16.9.1.4.3. Immediate
Release Capsules
16.9.1.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.1.4.5. Liquid
and Semi-solid Filled Capsules
16.9.1.4.6. Fast
Dispersible Tablets
16.9.1.4.7. Coating
of Tablets, Capsules and Pellets
16.9.1.4.8. Micro-encapsulation
Using Spray Drying
16.9.1.4.9. Oral
Liquids and Suspensions
16.9.1.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.1.4.11. Buccal
Delivery
16.9.1.4.12. Nasal
Sprays
16.9.1.4.13. Dental
Products
16.9.1.4.14. Pessaries
16.9.1.4.15. Others
16.9.1.5. France
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.1.5.1. Phase
I Trials
16.9.1.5.2. Phase
II/III trials
16.9.1.5.3. Others
16.9.1.6. France
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.1.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.1.6.2. Cardiovascular
Diseases
16.9.1.6.3. Metabolic
16.9.1.6.4. Autoimmune
and Neurological Disorders
16.9.1.6.5. Diabetes
16.9.1.6.6. Cancer
16.9.1.6.7. Infectious
Diseases
16.9.1.6.8. Others
16.9.1.7. France
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
16.9.1.7.1. Cell
Bank Preservation
16.9.1.7.2. Inoculum/Seed
Optimization
16.9.1.7.3. Media
Optimization
16.9.1.7.4. Formulation
16.9.1.7.5. Fermentation
Development
16.9.1.7.6. Harvest
Development
16.9.1.7.7. Lyophilization
Development
16.9.1.7.8. Analytical
Method Development
16.9.1.7.9. Process
Scale-Up
16.9.1.7.10. Liquid
Filling Services
16.9.1.7.11. Custom
Packaging Services
16.9.1.7.12. Others
16.9.2. The UK
16.9.2.1. The
UK Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
16.9.2.1.1. Pharma
Customers
16.9.2.1.2. Biotech
Customers
16.9.2.1.3. Others
16.9.2.2. The
UK Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
16.9.2.2.1. Active
Pharmaceutical Ingredients
16.9.2.2.2. Finished
Drugs
16.9.2.3. The
UK Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.2.3.1. Aerobic
16.9.2.3.2. Anaerobic
16.9.2.4. The
UK Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.2.4.1. Immediate
Release and Controlled Release Tablets
16.9.2.4.2. Multilayer
Tablets
16.9.2.4.3. Immediate
Release Capsules
16.9.2.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.2.4.5. Liquid
and Semi-solid Filled Capsules
16.9.2.4.6. Fast
Dispersible Tablets
16.9.2.4.7. Coating
of Tablets, Capsules and Pellets
16.9.2.4.8. Micro-encapsulation
Using Spray Drying
16.9.2.4.9. Oral
Liquids and Suspensions
16.9.2.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.2.4.11. Buccal
Delivery
16.9.2.4.12. Nasal
Sprays
16.9.2.4.13. Dental
Products
16.9.2.4.14. Pessaries
16.9.2.4.15. Others
16.9.2.5. The
UK Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.2.5.1. Phase
I Trials
16.9.2.5.2. Phase
II/III trials
16.9.2.5.3. Others
16.9.2.6. The
UK Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.2.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.2.6.2. Cardiovascular
Diseases
16.9.2.6.3. Metabolic
16.9.2.6.4. Autoimmune
and Neurological Disorders
16.9.2.6.5. Diabetes
16.9.2.6.6. Cancer
16.9.2.6.7. Infectious
Diseases
16.9.2.6.8. Others
16.9.2.7. The
UK Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
16.9.2.7.1. Cell
Bank Preservation
16.9.2.7.2. Inoculum/Seed
Optimization
16.9.2.7.3. Media
Optimization
16.9.2.7.4. Formulation
16.9.2.7.5. Fermentation
Development
16.9.2.7.6. Harvest
Development
16.9.2.7.7. Lyophilization
Development
16.9.2.7.8. Analytical
Method Development
16.9.2.7.9. Process
Scale-Up
16.9.2.7.10. Liquid
Filling Services
16.9.2.7.11. Custom
Packaging Services
16.9.2.7.12. Others
16.9.3. Spain
16.9.3.1. Spain
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
16.9.3.1.1. Pharma
Customers
16.9.3.1.2. Biotech
Customers
16.9.3.1.3. Others
16.9.3.2. Spain
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
16.9.3.2.1. Active
Pharmaceutical Ingredients
16.9.3.2.2. Finished
Drugs
16.9.3.3. Spain
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.3.3.1. Aerobic
16.9.3.3.2. Anaerobic
16.9.3.4. Spain
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.3.4.1. Immediate
Release and Controlled Release Tablets
16.9.3.4.2. Multilayer
Tablets
16.9.3.4.3. Immediate
Release Capsules
16.9.3.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.3.4.5. Liquid
and Semi-solid Filled Capsules
16.9.3.4.6. Fast
Dispersible Tablets
16.9.3.4.7. Coating
of Tablets, Capsules and Pellets
16.9.3.4.8. Micro-encapsulation
Using Spray Drying
16.9.3.4.9. Oral
Liquids and Suspensions
16.9.3.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.3.4.11. Buccal
Delivery
16.9.3.4.12. Nasal
Sprays
16.9.3.4.13. Dental
Products
16.9.3.4.14. Pessaries
16.9.3.4.15. Others
16.9.3.5. Spain
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.3.5.1. Phase
I Trials
16.9.3.5.2. Phase
II/III trials
16.9.3.5.3. Others
16.9.3.6. Spain
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.3.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.3.6.2. Cardiovascular
Diseases
16.9.3.6.3. Metabolic
16.9.3.6.4. Autoimmune
and Neurological Disorders
16.9.3.6.5. Diabetes
16.9.3.6.6. Cancer
16.9.3.6.7. Infectious
Diseases
16.9.3.6.8. Others
16.9.3.7. Spain
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
16.9.3.7.1. Cell
Bank Preservation
16.9.3.7.2. Inoculum/Seed
Optimization
16.9.3.7.3. Media
Optimization
16.9.3.7.4. Formulation
16.9.3.7.5. Fermentation
Development
16.9.3.7.6. Harvest
Development
16.9.3.7.7. Lyophilization
Development
16.9.3.7.8. Analytical
Method Development
16.9.3.7.9. Process
Scale-Up
16.9.3.7.10. Liquid
Filling Services
16.9.3.7.11. Custom
Packaging Services
16.9.3.7.12. Others
16.9.4. Germany
16.9.4.1. Germany
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
16.9.4.1.1. Pharma
Customers
16.9.4.1.2. Biotech
Customers
16.9.4.1.3. Others
16.9.4.2. Germany
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
16.9.4.2.1. Active
Pharmaceutical Ingredients
16.9.4.2.2. Finished
Drugs
16.9.4.3. Germany
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.4.3.1. Aerobic
16.9.4.3.2. Anaerobic
16.9.4.4. Germany
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.4.4.1. Immediate
Release and Controlled Release Tablets
16.9.4.4.2. Multilayer
Tablets
16.9.4.4.3. Immediate
Release Capsules
16.9.4.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.4.4.5. Liquid
and Semi-solid Filled Capsules
16.9.4.4.6. Fast
Dispersible Tablets
16.9.4.4.7. Coating
of Tablets, Capsules and Pellets
16.9.4.4.8. Micro-encapsulation
Using Spray Drying
16.9.4.4.9. Oral
Liquids and Suspensions
16.9.4.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.4.4.11. Buccal
Delivery
16.9.4.4.12. Nasal
Sprays
16.9.4.4.13. Dental
Products
16.9.4.4.14. Pessaries
16.9.4.4.15. Others
16.9.4.5. Germany
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.4.5.1. Phase
I Trials
16.9.4.5.2. Phase
II/III trials
16.9.4.5.3. Others
16.9.4.6. Germany
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.4.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.4.6.2. Cardiovascular
Diseases
16.9.4.6.3. Metabolic
16.9.4.6.4. Autoimmune
and Neurological Disorders
16.9.4.6.5. Diabetes
16.9.4.6.6. Cancer
16.9.4.6.7. Infectious
Diseases
16.9.4.6.8. Others
16.9.4.7. Germany
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
16.9.4.7.1. Cell
Bank Preservation
16.9.4.7.2. Inoculum/Seed
Optimization
16.9.4.7.3. Media
Optimization
16.9.4.7.4. Formulation
16.9.4.7.5. Fermentation
Development
16.9.4.7.6. Harvest
Development
16.9.4.7.7. Lyophilization
Development
16.9.4.7.8. Analytical
Method Development
16.9.4.7.9. Process
Scale-Up
16.9.4.7.10. Liquid
Filling Services
16.9.4.7.11. Custom
Packaging Services
16.9.4.7.12. Others
16.9.5. Italy
16.9.5.1. Italy
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
16.9.5.1.1. Pharma
Customers
16.9.5.1.2. Biotech
Customers
16.9.5.1.3. Others
16.9.5.2. Italy
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Product
16.9.5.2.1. Active
Pharmaceutical Ingredients
16.9.5.2.2. Finished
Drugs
16.9.5.3. Italy
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.5.3.1. Aerobic
16.9.5.3.2. Anaerobic
16.9.5.4. Italy
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.5.4.1. Immediate
Release and Controlled Release Tablets
16.9.5.4.2. Multilayer
Tablets
16.9.5.4.3. Immediate
Release Capsules
16.9.5.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.5.4.5. Liquid
and Semi-solid Filled Capsules
16.9.5.4.6. Fast
Dispersible Tablets
16.9.5.4.7. Coating
of Tablets, Capsules and Pellets
16.9.5.4.8. Micro-encapsulation
Using Spray Drying
16.9.5.4.9. Oral
Liquids and Suspensions
16.9.5.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.5.4.11. Buccal
Delivery
16.9.5.4.12. Nasal
Sprays
16.9.5.4.13. Dental
Products
16.9.5.4.14. Pessaries
16.9.5.4.15. Others
16.9.5.5. Italy
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.5.5.1. Phase
I Trials
16.9.5.5.2. Phase
II/III trials
16.9.5.5.3. Others
16.9.5.6. Italy
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.5.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.5.6.2. Cardiovascular
Diseases
16.9.5.6.3. Metabolic
16.9.5.6.4. Autoimmune
and Neurological Disorders
16.9.5.6.5. Diabetes
16.9.5.6.6. Cancer
16.9.5.6.7. Infectious
Diseases
16.9.5.6.8. Others
16.9.5.7. Italy
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
16.9.5.7.1. Cell
Bank Preservation
16.9.5.7.2. Inoculum/Seed
Optimization
16.9.5.7.3. Media
Optimization
16.9.5.7.4. Formulation
16.9.5.7.5. Fermentation
Development
16.9.5.7.6. Harvest
Development
16.9.5.7.7. Lyophilization
Development
16.9.5.7.8. Analytical
Method Development
16.9.5.7.9. Process
Scale-Up
16.9.5.7.10. Liquid
Filling Services
16.9.5.7.11. Custom
Packaging Services
16.9.5.7.12. Others
16.9.6. Nordic
Countries
16.9.6.1. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
16.9.6.1.1. Pharma
Customers
16.9.6.1.2. Biotech
Customers
16.9.6.1.3. Others
16.9.6.2. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
16.9.6.2.1. Active
Pharmaceutical Ingredients
16.9.6.2.2. Finished
Drugs
16.9.6.3. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.6.3.1. Aerobic
16.9.6.3.2. Anaerobic
16.9.6.4. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.6.4.1. Immediate
Release and Controlled Release Tablets
16.9.6.4.2. Multilayer
Tablets
16.9.6.4.3. Immediate
Release Capsules
16.9.6.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.6.4.5. Liquid
and Semi-solid Filled Capsules
16.9.6.4.6. Fast
Dispersible Tablets
16.9.6.4.7. Coating
of Tablets, Capsules and Pellets
16.9.6.4.8. Micro-encapsulation
Using Spray Drying
16.9.6.4.9. Oral
Liquids and Suspensions
16.9.6.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.6.4.11. Buccal
Delivery
16.9.6.4.12. Nasal
Sprays
16.9.6.4.13. Dental
Products
16.9.6.4.14. Pessaries
16.9.6.4.15. Others
16.9.6.5. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.6.5.1. Phase
I Trials
16.9.6.5.2. Phase
II/III trials
16.9.6.5.3. Others
16.9.6.6. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.6.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.6.6.2. Cardiovascular
Diseases
16.9.6.6.3. Metabolic
16.9.6.6.4. Autoimmune
and Neurological Disorders
16.9.6.6.5. Diabetes
16.9.6.6.6. Cancer
16.9.6.6.7. Infectious
Diseases
16.9.6.6.8. Others
16.9.6.7. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
16.9.6.7.1. Cell
Bank Preservation
16.9.6.7.2. Inoculum/Seed
Optimization
16.9.6.7.3. Media
Optimization
16.9.6.7.4. Formulation
16.9.6.7.5. Fermentation
Development
16.9.6.7.6. Harvest
Development
16.9.6.7.7. Lyophilization
Development
16.9.6.7.8. Analytical
Method Development
16.9.6.7.9. Process
Scale-Up
16.9.6.7.10. Liquid
Filling Services
16.9.6.7.11. Custom
Packaging Services
16.9.6.7.12. Others
16.9.6.8. Nordic
Countries Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Country
16.9.6.8.1. Denmark
16.9.6.8.2. Finland
16.9.6.8.3. Iceland
16.9.6.8.4. Sweden
16.9.6.8.5. Norway
16.9.7. Benelux
Union
16.9.7.1. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
16.9.7.1.1. Pharma
Customers
16.9.7.1.2. Biotech
Customers
16.9.7.1.3. Others
16.9.7.2. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
16.9.7.2.1. Active
Pharmaceutical Ingredients
16.9.7.2.2. Finished
Drugs
16.9.7.3. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.7.3.1. Aerobic
16.9.7.3.2. Anaerobic
16.9.7.4. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.7.4.1. Immediate
Release and Controlled Release Tablets
16.9.7.4.2. Multilayer
Tablets
16.9.7.4.3. Immediate
Release Capsules
16.9.7.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.7.4.5. Liquid
and Semi-solid Filled Capsules
16.9.7.4.6. Fast
Dispersible Tablets
16.9.7.4.7. Coating
of Tablets, Capsules and Pellets
16.9.7.4.8. Micro-encapsulation
Using Spray Drying
16.9.7.4.9. Oral
Liquids and Suspensions
16.9.7.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.7.4.11. Buccal
Delivery
16.9.7.4.12. Nasal
Sprays
16.9.7.4.13. Dental
Products
16.9.7.4.14. Pessaries
16.9.7.4.15. Others
16.9.7.5. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.7.5.1. Phase
I Trials
16.9.7.5.2. Phase
II/III trials
16.9.7.5.3. Others
16.9.7.6. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.7.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.7.6.2. Cardiovascular
Diseases
16.9.7.6.3. Metabolic
16.9.7.6.4. Autoimmune
and Neurological Disorders
16.9.7.6.5. Diabetes
16.9.7.6.6. Cancer
16.9.7.6.7. Infectious
Diseases
16.9.7.6.8. Others
16.9.7.7. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
16.9.7.7.1. Cell
Bank Preservation
16.9.7.7.2. Inoculum/Seed
Optimization
16.9.7.7.3. Media
Optimization
16.9.7.7.4. Formulation
16.9.7.7.5. Fermentation
Development
16.9.7.7.6. Harvest
Development
16.9.7.7.7. Lyophilization
Development
16.9.7.7.8. Analytical
Method Development
16.9.7.7.9. Process
Scale-Up
16.9.7.7.10. Liquid
Filling Services
16.9.7.7.11. Custom
Packaging Services
16.9.7.7.12. Others
16.9.7.8. Benelux
Union Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Country
16.9.7.8.1. Belgium
16.9.7.8.2. The
Netherlands
16.9.7.8.3. Luxembourg
16.9.8. Rest of
Europe
16.9.8.1. Rest
of Europe Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
16.9.8.1.1. Pharma
Customers
16.9.8.1.2. Biotech
Customers
16.9.8.1.3. Others
16.9.8.2. Rest
of Europe Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
16.9.8.2.1. Active
Pharmaceutical Ingredients
16.9.8.2.2. Finished
Drugs
16.9.8.3. Rest
of Europe Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
16.9.8.3.1. Aerobic
16.9.8.3.2. Anaerobic
16.9.8.4. Rest
of Europe Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
16.9.8.4.1. Immediate
Release and Controlled Release Tablets
16.9.8.4.2. Multilayer
Tablets
16.9.8.4.3. Immediate
Release Capsules
16.9.8.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
16.9.8.4.5. Liquid
and Semi-solid Filled Capsules
16.9.8.4.6. Fast
Dispersible Tablets
16.9.8.4.7. Coating
of Tablets, Capsules and Pellets
16.9.8.4.8. Micro-encapsulation
Using Spray Drying
16.9.8.4.9. Oral
Liquids and Suspensions
16.9.8.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
16.9.8.4.11. Buccal
Delivery
16.9.8.4.12. Nasal
Sprays
16.9.8.4.13. Dental
Products
16.9.8.4.14. Pessaries
16.9.8.4.15. Others
16.9.8.5. Rest
of Europe Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.9.8.5.1. Phase
I Trials
16.9.8.5.2. Phase
II/III trials
16.9.8.5.3. Others
16.9.8.6. Rest
of Europe Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
16.9.8.6.1. Gastrointestinal
Disorders and Food Allergies
16.9.8.6.2. Cardiovascular
Diseases
16.9.8.6.3. Metabolic
16.9.8.6.4. Autoimmune
and Neurological Disorders
16.9.8.6.5. Diabetes
16.9.8.6.6. Cancer
16.9.8.6.7. Infectious
Diseases
16.9.8.6.8. Others
16.9.8.7. Rest
of Europe Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
16.9.8.7.1. Cell
Bank Preservation
16.9.8.7.2. Inoculum/Seed
Optimization
16.9.8.7.3. Media
Optimization
16.9.8.7.4. Formulation
16.9.8.7.5. Fermentation
Development
16.9.8.7.6. Harvest
Development
16.9.8.7.7. Lyophilization
Development
16.9.8.7.8. Analytical
Method Development
16.9.8.7.9. Process
Scale-Up
16.9.8.7.10. Liquid
Filling Services
16.9.8.7.11. Custom
Packaging Services
16.9.8.7.12. Others
16.10. Key
Segment for Channeling Investments
16.10.1. By
Country
16.10.2. By End
User
16.10.3. By
Product
16.10.4. By
Type of Fermentation
16.10.5. By
Dosage Forms
16.10.6. By
Clinical Phases
16.10.7. By
Disease Indication
16.10.8. By
Services
17. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Analysis and Forecasts, 2022 - 2030
17.1. Overview
17.1.1. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn)
17.2. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
17.2.1. Pharma Customers
17.2.2. Biotech
Customers
17.2.3. Others
17.3. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
17.3.1. Active
Pharmaceutical Ingredients
17.3.2. Finished
Drugs
17.4. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.4.1. Aerobic
17.4.2. Anaerobic
17.5. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.5.1. Immediate
Release and Controlled Release Tablets
17.5.2. Multilayer
Tablets
17.5.3. Immediate
Release Capsules
17.5.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.5.5. Liquid
and Semi-solid Filled Capsules
17.5.6. Fast
Dispersible Tablets
17.5.7. Coating
of Tablets, Capsules and Pellets
17.5.8. Micro-encapsulation
Using Spray Drying
17.5.9. Oral
Liquids and Suspensions
17.5.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.5.11. Buccal
Delivery
17.5.12. Nasal
Sprays
17.5.13. Dental
Products
17.5.14. Pessaries
17.5.15. Others
17.6. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.6.1. Phase I
Trials
17.6.2. Phase
II/III trials
17.6.3. Others
17.7. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
17.7.1. Gastrointestinal
Disorders and Food Allergies
17.7.2. Cardiovascular
Diseases
17.7.3. Metabolic
17.7.4. Autoimmune
and Neurological Disorders
17.7.5. Diabetes
17.7.6. Cancer
17.7.7. Infectious
Diseases
17.7.8. Others
17.8. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
17.8.1. Cell
Bank Preservation
17.8.2. Inoculum/Seed
Optimization
17.8.3. Media
Optimization
17.8.4. Formulation
17.8.5. Fermentation
Development
17.8.6. Harvest
Development
17.8.7. Lyophilization
Development
17.8.8. Analytical
Method Development
17.8.9. Process
Scale-Up
17.8.10. Liquid
Filling Services
17.8.11. Custom
Packaging Services
17.8.12. Others
17.9. Asia
Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Country
17.9.1. China
17.9.1.1. China
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
17.9.1.1.1. Pharma
Customers
17.9.1.1.2. Biotech
Customers
17.9.1.1.3. Others
17.9.1.2. China
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
17.9.1.2.1. Active
Pharmaceutical Ingredients
17.9.1.2.2. Finished
Drugs
17.9.1.3. China
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.1.3.1. Aerobic
17.9.1.3.2. Anaerobic
17.9.1.4. China
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.1.4.1. Immediate
Release and Controlled Release Tablets
17.9.1.4.2. Multilayer
Tablets
17.9.1.4.3. Immediate
Release Capsules
17.9.1.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.1.4.5. Liquid
and Semi-solid Filled Capsules
17.9.1.4.6. Fast
Dispersible Tablets
17.9.1.4.7. Coating
of Tablets, Capsules and Pellets
17.9.1.4.8. Micro-encapsulation
Using Spray Drying
17.9.1.4.9. Oral
Liquids and Suspensions
17.9.1.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.1.4.11. Buccal
Delivery
17.9.1.4.12. Nasal
Sprays
17.9.1.4.13. Dental
Products
17.9.1.4.14. Pessaries
17.9.1.4.15. Others
17.9.1.5. China
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.1.5.1. Phase
I Trials
17.9.1.5.2. Phase
II/III trials
17.9.1.5.3. Others
17.9.1.6. China
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.1.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.1.6.2. Cardiovascular
Diseases
17.9.1.6.3. Metabolic
17.9.1.6.4. Autoimmune
and Neurological Disorders
17.9.1.6.5. Diabetes
17.9.1.6.6. Cancer
17.9.1.6.7. Infectious
Diseases
17.9.1.6.8. Others
17.9.1.7. China
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
17.9.1.7.1. Cell
Bank Preservation
17.9.1.7.2. Inoculum/Seed
Optimization
17.9.1.7.3. Media
Optimization
17.9.1.7.4. Formulation
17.9.1.7.5. Fermentation
Development
17.9.1.7.6. Harvest
Development
17.9.1.7.7. Lyophilization
Development
17.9.1.7.8. Analytical
Method Development
17.9.1.7.9. Process
Scale-Up
17.9.1.7.10. Liquid
Filling Services
17.9.1.7.11. Custom
Packaging Services
17.9.1.7.12. Others
17.9.2. Japan
17.9.2.1. Japan
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
17.9.2.1.1. Pharma
Customers
17.9.2.1.2. Biotech
Customers
17.9.2.1.3. Others
17.9.2.2. Japan
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
17.9.2.2.1. Active
Pharmaceutical Ingredients
17.9.2.2.2. Finished
Drugs
17.9.2.3. Japan
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.2.3.1. Aerobic
17.9.2.3.2. Anaerobic
17.9.2.4. Japan
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.2.4.1. Immediate
Release and Controlled Release Tablets
17.9.2.4.2. Multilayer
Tablets
17.9.2.4.3. Immediate
Release Capsules
17.9.2.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.2.4.5. Liquid
and Semi-solid Filled Capsules
17.9.2.4.6. Fast
Dispersible Tablets
17.9.2.4.7. Coating
of Tablets, Capsules and Pellets
17.9.2.4.8. Micro-encapsulation
Using Spray Drying
17.9.2.4.9. Oral
Liquids and Suspensions
17.9.2.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.2.4.11. Buccal
Delivery
17.9.2.4.12. Nasal
Sprays
17.9.2.4.13. Dental
Products
17.9.2.4.14. Pessaries
17.9.2.4.15. Others
17.9.2.5. Japan
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.2.5.1. Phase
I Trials
17.9.2.5.2. Phase
II/III trials
17.9.2.5.3. Others
17.9.2.6. Japan
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.2.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.2.6.2. Cardiovascular
Diseases
17.9.2.6.3. Metabolic
17.9.2.6.4. Autoimmune
and Neurological Disorders
17.9.2.6.5. Diabetes
17.9.2.6.6. Cancer
17.9.2.6.7. Infectious
Diseases
17.9.2.6.8. Others
17.9.2.7. Japan
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Revenue
(US$ Mn) and Forecasts, By Services
17.9.2.7.1. Cell
Bank Preservation
17.9.2.7.2. Inoculum/Seed
Optimization
17.9.2.7.3. Media
Optimization
17.9.2.7.4. Formulation
17.9.2.7.5. Fermentation
Development
17.9.2.7.6. Harvest
Development
17.9.2.7.7. Lyophilization
Development
17.9.2.7.8. Analytical
Method Development
17.9.2.7.9. Process
Scale-Up
17.9.2.7.10. Liquid
Filling Services
17.9.2.7.11. Custom
Packaging Services
17.9.2.7.12. Others
17.9.3. India
17.9.3.1. India
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
17.9.3.1.1. Pharma
Customers
17.9.3.1.2. Biotech
Customers
17.9.3.1.3. Others
17.9.3.2. India
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
17.9.3.2.1. Active
Pharmaceutical Ingredients
17.9.3.2.2. Finished
Drugs
17.9.3.3. India
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.3.3.1. Aerobic
17.9.3.3.2. Anaerobic
17.9.3.4. India
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.3.4.1. Immediate
Release and Controlled Release Tablets
17.9.3.4.2. Multilayer
Tablets
17.9.3.4.3. Immediate
Release Capsules
17.9.3.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.3.4.5. Liquid
and Semi-solid Filled Capsules
17.9.3.4.6. Fast
Dispersible Tablets
17.9.3.4.7. Coating
of Tablets, Capsules and Pellets
17.9.3.4.8. Micro-encapsulation
Using Spray Drying
17.9.3.4.9. Oral
Liquids and Suspensions
17.9.3.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.3.4.11. Buccal
Delivery
17.9.3.4.12. Nasal
Sprays
17.9.3.4.13. Dental
Products
17.9.3.4.14. Pessaries
17.9.3.4.15. Others
17.9.3.5. India
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.3.5.1. Phase
I Trials
17.9.3.5.2. Phase
II/III trials
17.9.3.5.3. Others
17.9.3.6. India
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.3.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.3.6.2. Cardiovascular
Diseases
17.9.3.6.3. Metabolic
17.9.3.6.4. Autoimmune
and Neurological Disorders
17.9.3.6.5. Diabetes
17.9.3.6.6. Cancer
17.9.3.6.7. Infectious
Diseases
17.9.3.6.8. Others
17.9.3.7. India
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
17.9.3.7.1. Cell
Bank Preservation
17.9.3.7.2. Inoculum/Seed
Optimization
17.9.3.7.3. Media
Optimization
17.9.3.7.4. Formulation
17.9.3.7.5. Fermentation
Development
17.9.3.7.6. Harvest
Development
17.9.3.7.7. Lyophilization
Development
17.9.3.7.8. Analytical
Method Development
17.9.3.7.9. Process
Scale-Up
17.9.3.7.10. Liquid
Filling Services
17.9.3.7.11. Custom
Packaging Services
17.9.3.7.12. Others
17.9.4. New
Zealand
17.9.4.1. New
Zealand Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
17.9.4.1.1. Pharma
Customers
17.9.4.1.2. Biotech
Customers
17.9.4.1.3. Others
17.9.4.2. New
Zealand Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
17.9.4.2.1. Active
Pharmaceutical Ingredients
17.9.4.2.2. Finished
Drugs
17.9.4.3. New
Zealand Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.4.3.1. Aerobic
17.9.4.3.2. Anaerobic
17.9.4.4. New
Zealand Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.4.4.1. Immediate
Release and Controlled Release Tablets
17.9.4.4.2. Multilayer
Tablets
17.9.4.4.3. Immediate
Release Capsules
17.9.4.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.4.4.5. Liquid
and Semi-solid Filled Capsules
17.9.4.4.6. Fast
Dispersible Tablets
17.9.4.4.7. Coating
of Tablets, Capsules and Pellets
17.9.4.4.8. Micro-encapsulation
Using Spray Drying
17.9.4.4.9. Oral
Liquids and Suspensions
17.9.4.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.4.4.11. Buccal
Delivery
17.9.4.4.12. Nasal
Sprays
17.9.4.4.13. Dental
Products
17.9.4.4.14. Pessaries
17.9.4.4.15. Others
17.9.4.5. New
Zealand Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.4.5.1. Phase
I Trials
17.9.4.5.2. Phase
II/III trials
17.9.4.5.3. Others
17.9.4.6. New
Zealand Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.4.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.4.6.2. Cardiovascular
Diseases
17.9.4.6.3. Metabolic
17.9.4.6.4. Autoimmune
and Neurological Disorders
17.9.4.6.5. Diabetes
17.9.4.6.6. Cancer
17.9.4.6.7. Infectious
Diseases
17.9.4.6.8. Others
17.9.4.7. New
Zealand Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
17.9.4.7.1. Cell
Bank Preservation
17.9.4.7.2. Inoculum/Seed
Optimization
17.9.4.7.3. Media
Optimization
17.9.4.7.4. Formulation
17.9.4.7.5. Fermentation
Development
17.9.4.7.6. Harvest
Development
17.9.4.7.7. Lyophilization
Development
17.9.4.7.8. Analytical
Method Development
17.9.4.7.9. Process
Scale-Up
17.9.4.7.10. Liquid
Filling Services
17.9.4.7.11. Custom
Packaging Services
17.9.4.7.12. Others
17.9.5. Australia
17.9.5.1. Australia
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
17.9.5.1.1. Pharma
Customers
17.9.5.1.2. Biotech
Customers
17.9.5.1.3. Others
17.9.5.2. Australia
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
17.9.5.2.1. Active
Pharmaceutical Ingredients
17.9.5.2.2. Finished
Drugs
17.9.5.3. Australia
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.5.3.1. Aerobic
17.9.5.3.2. Anaerobic
17.9.5.4. Australia
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.5.4.1. Immediate
Release and Controlled Release Tablets
17.9.5.4.2. Multilayer
Tablets
17.9.5.4.3. Immediate
Release Capsules
17.9.5.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.5.4.5. Liquid
and Semi-solid Filled Capsules
17.9.5.4.6. Fast
Dispersible Tablets
17.9.5.4.7. Coating
of Tablets, Capsules and Pellets
17.9.5.4.8. Micro-encapsulation
Using Spray Drying
17.9.5.4.9. Oral
Liquids and Suspensions
17.9.5.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.5.4.11. Buccal
Delivery
17.9.5.4.12. Nasal
Sprays
17.9.5.4.13. Dental
Products
17.9.5.4.14. Pessaries
17.9.5.4.15. Others
17.9.5.5. Australia
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.5.5.1. Phase
I Trials
17.9.5.5.2. Phase
II/III trials
17.9.5.5.3. Others
17.9.5.6. Australia
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.5.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.5.6.2. Cardiovascular
Diseases
17.9.5.6.3. Metabolic
17.9.5.6.4. Autoimmune
and Neurological Disorders
17.9.5.6.5. Diabetes
17.9.5.6.6. Cancer
17.9.5.6.7. Infectious
Diseases
17.9.5.6.8. Others
17.9.5.7. Australia
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
17.9.5.7.1. Cell
Bank Preservation
17.9.5.7.2. Inoculum/Seed
Optimization
17.9.5.7.3. Media
Optimization
17.9.5.7.4. Formulation
17.9.5.7.5. Fermentation
Development
17.9.5.7.6. Harvest
Development
17.9.5.7.7. Lyophilization
Development
17.9.5.7.8. Analytical
Method Development
17.9.5.7.9. Process
Scale-Up
17.9.5.7.10. Liquid
Filling Services
17.9.5.7.11. Custom
Packaging Services
17.9.5.7.12. Others
17.9.6. South
Korea
17.9.6.1. South
Korea Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
17.9.6.1.1. Pharma
Customers
17.9.6.1.2. Biotech
Customers
17.9.6.1.3. Others
17.9.6.2. South
Korea Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
17.9.6.2.1. Active
Pharmaceutical Ingredients
17.9.6.2.2. Finished
Drugs
17.9.6.3. South
Korea Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.6.3.1. Aerobic
17.9.6.3.2. Anaerobic
17.9.6.4. South
Korea Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.6.4.1. Immediate
Release and Controlled Release Tablets
17.9.6.4.2. Multilayer
Tablets
17.9.6.4.3. Immediate
Release Capsules
17.9.6.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.6.4.5. Liquid
and Semi-solid Filled Capsules
17.9.6.4.6. Fast
Dispersible Tablets
17.9.6.4.7. Coating
of Tablets, Capsules and Pellets
17.9.6.4.8. Micro-encapsulation
Using Spray Drying
17.9.6.4.9. Oral
Liquids and Suspensions
17.9.6.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.6.4.11. Buccal
Delivery
17.9.6.4.12. Nasal
Sprays
17.9.6.4.13. Dental
Products
17.9.6.4.14. Pessaries
17.9.6.4.15. Others
17.9.6.5. South
Korea Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.6.5.1. Phase
I Trials
17.9.6.5.2. Phase
II/III trials
17.9.6.5.3. Others
17.9.6.6. South
Korea Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.6.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.6.6.2. Cardiovascular
Diseases
17.9.6.6.3. Metabolic
17.9.6.6.4. Autoimmune
and Neurological Disorders
17.9.6.6.5. Diabetes
17.9.6.6.6. Cancer
17.9.6.6.7. Infectious
Diseases
17.9.6.6.8. Others
17.9.6.7. South
Korea Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
17.9.6.7.1. Cell
Bank Preservation
17.9.6.7.2. Inoculum/Seed
Optimization
17.9.6.7.3. Media
Optimization
17.9.6.7.4. Formulation
17.9.6.7.5. Fermentation
Development
17.9.6.7.6. Harvest
Development
17.9.6.7.7. Lyophilization
Development
17.9.6.7.8. Analytical
Method Development
17.9.6.7.9. Process
Scale-Up
17.9.6.7.10. Liquid
Filling Services
17.9.6.7.11. Custom
Packaging Services
17.9.6.7.12. Others
17.9.7. Southeast
Asia
17.9.7.1. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
17.9.7.1.1. Pharma
Customers
17.9.7.1.2. Biotech
Customers
17.9.7.1.3. Others
17.9.7.2. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
17.9.7.2.1. Active
Pharmaceutical Ingredients
17.9.7.2.2. Finished
Drugs
17.9.7.3. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.7.3.1. Aerobic
17.9.7.3.2. Anaerobic
17.9.7.4. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.7.4.1. Immediate
Release and Controlled Release Tablets
17.9.7.4.2. Multilayer
Tablets
17.9.7.4.3. Immediate
Release Capsules
17.9.7.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.7.4.5. Liquid
and Semi-solid Filled Capsules
17.9.7.4.6. Fast
Dispersible Tablets
17.9.7.4.7. Coating
of Tablets, Capsules and Pellets
17.9.7.4.8. Micro-encapsulation
Using Spray Drying
17.9.7.4.9. Oral
Liquids and Suspensions
17.9.7.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.7.4.11. Buccal
Delivery
17.9.7.4.12. Nasal
Sprays
17.9.7.4.13. Dental
Products
17.9.7.4.14. Pessaries
17.9.7.4.15. Others
17.9.7.5. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.7.5.1. Phase
I Trials
17.9.7.5.2. Phase
II/III trials
17.9.7.5.3. Others
17.9.7.6. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.7.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.7.6.2. Cardiovascular
Diseases
17.9.7.6.3. Metabolic
17.9.7.6.4. Autoimmune
and Neurological Disorders
17.9.7.6.5. Diabetes
17.9.7.6.6. Cancer
17.9.7.6.7. Infectious
Diseases
17.9.7.6.8. Others
17.9.7.7. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
17.9.7.7.1. Cell
Bank Preservation
17.9.7.7.2. Inoculum/Seed
Optimization
17.9.7.7.3. Media
Optimization
17.9.7.7.4. Formulation
17.9.7.7.5. Fermentation
Development
17.9.7.7.6. Harvest
Development
17.9.7.7.7. Lyophilization
Development
17.9.7.7.8. Analytical
Method Development
17.9.7.7.9. Process
Scale-Up
17.9.7.7.10. Liquid
Filling Services
17.9.7.7.11. Custom
Packaging Services
17.9.7.7.12. Others
17.9.7.8. Southeast
Asia Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Country
17.9.7.8.1. Indonesia
17.9.7.8.2. Thailand
17.9.7.8.3. Malaysia
17.9.7.8.4. Singapore
17.9.7.8.5. Rest
of Southeast Asia
17.9.8. Rest of
Asia Pacific
17.9.8.1. Rest
of Asia Pacific Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By End User
17.9.8.1.1. Pharma
Customers
17.9.8.1.2. Biotech
Customers
17.9.8.1.3. Others
17.9.8.2. Rest
of Asia Pacific Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Product
17.9.8.2.1. Active
Pharmaceutical Ingredients
17.9.8.2.2. Finished
Drugs
17.9.8.3. Rest
of Asia Pacific Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
17.9.8.3.1. Aerobic
17.9.8.3.2. Anaerobic
17.9.8.4. Rest
of Asia Pacific Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
17.9.8.4.1. Immediate
Release and Controlled Release Tablets
17.9.8.4.2. Multilayer
Tablets
17.9.8.4.3. Immediate
Release Capsules
17.9.8.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
17.9.8.4.5. Liquid
and Semi-solid Filled Capsules
17.9.8.4.6. Fast
Dispersible Tablets
17.9.8.4.7. Coating
of Tablets, Capsules and Pellets
17.9.8.4.8. Micro-encapsulation
Using Spray Drying
17.9.8.4.9. Oral
Liquids and Suspensions
17.9.8.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
17.9.8.4.11. Buccal
Delivery
17.9.8.4.12. Nasal
Sprays
17.9.8.4.13. Dental
Products
17.9.8.4.14. Pessaries
17.9.8.4.15. Others
17.9.8.5. Rest
of Asia Pacific Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
17.9.8.5.1. Phase
I Trials
17.9.8.5.2. Phase
II/III trials
17.9.8.5.3. Others
17.9.8.6. Rest
of Asia Pacific Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Disease Indication
17.9.8.6.1. Gastrointestinal
Disorders and Food Allergies
17.9.8.6.2. Cardiovascular
Diseases
17.9.8.6.3. Metabolic
17.9.8.6.4. Autoimmune
and Neurological Disorders
17.9.8.6.5. Diabetes
17.9.8.6.6. Cancer
17.9.8.6.7. Infectious
Diseases
17.9.8.6.8. Others
17.9.8.7. Rest
of Asia Pacific Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Services
17.9.8.7.1. Cell
Bank Preservation
17.9.8.7.2. Inoculum/Seed
Optimization
17.9.8.7.3. Media
Optimization
17.9.8.7.4. Formulation
17.9.8.7.5. Fermentation
Development
17.9.8.7.6. Harvest
Development
17.9.8.7.7. Lyophilization
Development
17.9.8.7.8. Analytical
Method Development
17.9.8.7.9. Process
Scale-Up
17.9.8.7.10. Liquid
Filling Services
17.9.8.7.11. Custom
Packaging Services
17.9.8.7.12. Others
17.10. Key
Segment for Channeling Investments
17.10.1. By
Country
17.10.2. By End
User
17.10.3. By
Product
17.10.4. By
Type of Fermentation
17.10.5. By
Dosage Forms
17.10.6. By
Clinical Phases
17.10.7. By
Disease Indication
17.10.8. By
Services
18. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Analysis and Forecasts, 2022 - 2030
18.1. Overview
18.1.1. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn)
18.2. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By End User
18.2.1. Pharma
Customers
18.2.2. Biotech
Customers
18.2.3. Others
18.3. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Product
18.3.1. Active
Pharmaceutical Ingredients
18.3.2. Finished
Drugs
18.4. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
18.4.1. Aerobic
18.4.2. Anaerobic
18.5. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
18.5.1. Immediate
Release and Controlled Release Tablets
18.5.2. Multilayer
Tablets
18.5.3. Immediate
Release Capsules
18.5.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
18.5.5. Liquid
and Semi-solid Filled Capsules
18.5.6. Fast
Dispersible Tablets
18.5.7. Coating
of Tablets, Capsules and Pellets
18.5.8. Micro-encapsulation
Using Spray Drying
18.5.9. Oral
Liquids and Suspensions
18.5.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
18.5.11. Buccal
Delivery
18.5.12. Nasal
Sprays
18.5.13. Dental
Products
18.5.14. Pessaries
18.5.15. Others
18.6. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
18.6.1. Phase I
Trials
18.6.2. Phase
II/III trials
18.6.3. Others
18.7. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Disease Indication
18.7.1. Gastrointestinal
Disorders and Food Allergies
18.7.2. Cardiovascular
Diseases
18.7.3. Metabolic
18.7.4. Autoimmune
and Neurological Disorders
18.7.5. Diabetes
18.7.6. Cancer
18.7.7. Infectious
Diseases
18.7.8. Others
18.8. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Services
18.8.1. Cell
Bank Preservation
18.8.2. Inoculum/Seed
Optimization
18.8.3. Media
Optimization
18.8.4. Formulation
18.8.5. Fermentation
Development
18.8.6. Harvest
Development
18.8.7. Lyophilization
Development
18.8.8. Analytical
Method Development
18.8.9. Process
Scale-Up
18.8.10. Liquid
Filling Services
18.8.11. Custom
Packaging Services
18.8.12. Others
18.9. Middle
East and Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Country
18.9.1. Saudi
Arabia
18.9.1.1. Saudi
Arabia Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
18.9.1.1.1. Pharma
Customers
18.9.1.1.2. Biotech
Customers
18.9.1.1.3. Others
18.9.1.2. Saudi
Arabia Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
18.9.1.2.1. Active
Pharmaceutical Ingredients
18.9.1.2.2. Finished
Drugs
18.9.1.3. Saudi
Arabia Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
18.9.1.3.1. Aerobic
18.9.1.3.2. Anaerobic
18.9.1.4. Saudi
Arabia Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
18.9.1.4.1. Immediate
Release and Controlled Release Tablets
18.9.1.4.2. Multilayer
Tablets
18.9.1.4.3. Immediate
Release Capsules
18.9.1.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
18.9.1.4.5. Liquid
and Semi-solid Filled Capsules
18.9.1.4.6. Fast
Dispersible Tablets
18.9.1.4.7. Coating
of Tablets, Capsules and Pellets
18.9.1.4.8. Micro-encapsulation
Using Spray Drying
18.9.1.4.9. Oral
Liquids and Suspensions
18.9.1.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
18.9.1.4.11. Buccal
Delivery
18.9.1.4.12. Nasal
Sprays
18.9.1.4.13. Dental
Products
18.9.1.4.14. Pessaries
18.9.1.4.15. Others
18.9.1.5. Saudi
Arabia Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
18.9.1.5.1. Phase
I Trials
18.9.1.5.2. Phase
II/III trials
18.9.1.5.3. Others
18.9.1.6. Saudi
Arabia Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
18.9.1.6.1. Gastrointestinal
Disorders and Food Allergies
18.9.1.6.2. Cardiovascular
Diseases
18.9.1.6.3. Metabolic
18.9.1.6.4. Autoimmune
and Neurological Disorders
18.9.1.6.5. Diabetes
18.9.1.6.6. Cancer
18.9.1.6.7. Infectious
Diseases
18.9.1.6.8. Others
18.9.1.7. Saudi
Arabia Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
18.9.1.7.1. Cell
Bank Preservation
18.9.1.7.2. Inoculum/Seed
Optimization
18.9.1.7.3. Media
Optimization
18.9.1.7.4. Formulation
18.9.1.7.5. Fermentation
Development
18.9.1.7.6. Harvest
Development
18.9.1.7.7. Lyophilization
Development
18.9.1.7.8. Analytical
Method Development
18.9.1.7.9. Process
Scale-Up
18.9.1.7.10. Liquid
Filling Services
18.9.1.7.11. Custom
Packaging Services
18.9.1.7.12. Others
18.9.2. UAE
18.9.2.1. UAE
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
18.9.2.1.1. Pharma
Customers
18.9.2.1.2. Biotech
Customers
18.9.2.1.3. Others
18.9.2.2. UAE
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
18.9.2.2.1. Active
Pharmaceutical Ingredients
18.9.2.2.2. Finished
Drugs
18.9.2.3. UAE
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
18.9.2.3.1. Aerobic
18.9.2.3.2. Anaerobic
18.9.2.4. UAE
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
18.9.2.4.1. Immediate
Release and Controlled Release Tablets
18.9.2.4.2. Multilayer
Tablets
18.9.2.4.3. Immediate
Release Capsules
18.9.2.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
18.9.2.4.5. Liquid
and Semi-solid Filled Capsules
18.9.2.4.6. Fast
Dispersible Tablets
18.9.2.4.7. Coating
of Tablets, Capsules and Pellets
18.9.2.4.8. Micro-encapsulation
Using Spray Drying
18.9.2.4.9. Oral
Liquids and Suspensions
18.9.2.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
18.9.2.4.11. Buccal
Delivery
18.9.2.4.12. Nasal
Sprays
18.9.2.4.13. Dental
Products
18.9.2.4.14. Pessaries
18.9.2.4.15. Others
18.9.2.5. UAE
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
18.9.2.5.1. Phase
I Trials
18.9.2.5.2. Phase
II/III trials
18.9.2.5.3. Others
18.9.2.6. UAE
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
18.9.2.6.1. Gastrointestinal
Disorders and Food Allergies
18.9.2.6.2. Cardiovascular
Diseases
18.9.2.6.3. Metabolic
18.9.2.6.4. Autoimmune
and Neurological Disorders
18.9.2.6.5. Diabetes
18.9.2.6.6. Cancer
18.9.2.6.7. Infectious
Diseases
18.9.2.6.8. Others
18.9.2.7. UAE
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
18.9.2.7.1. Cell
Bank Preservation
18.9.2.7.2. Inoculum/Seed
Optimization
18.9.2.7.3. Media
Optimization
18.9.2.7.4. Formulation
18.9.2.7.5. Fermentation
Development
18.9.2.7.6. Harvest
Development
18.9.2.7.7. Lyophilization
Development
18.9.2.7.8. Analytical
Method Development
18.9.2.7.9. Process
Scale-Up
18.9.2.7.10. Liquid
Filling Services
18.9.2.7.11. Custom
Packaging Services
18.9.2.7.12. Others
18.9.3. Egypt
18.9.3.1. Egypt
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
18.9.3.1.1. Pharma
Customers
18.9.3.1.2. Biotech
Customers
18.9.3.1.3. Others
18.9.3.2. Egypt
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
18.9.3.2.1. Active
Pharmaceutical Ingredients
18.9.3.2.2. Finished
Drugs
18.9.3.3. Egypt
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
18.9.3.3.1. Aerobic
18.9.3.3.2. Anaerobic
18.9.3.4. Egypt
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
18.9.3.4.1. Immediate
Release and Controlled Release Tablets
18.9.3.4.2. Multilayer
Tablets
18.9.3.4.3. Immediate
Release Capsules
18.9.3.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
18.9.3.4.5. Liquid
and Semi-solid Filled Capsules
18.9.3.4.6. Fast
Dispersible Tablets
18.9.3.4.7. Coating
of Tablets, Capsules and Pellets
18.9.3.4.8. Micro-encapsulation
Using Spray Drying
18.9.3.4.9. Oral
Liquids and Suspensions
18.9.3.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
18.9.3.4.11. Buccal
Delivery
18.9.3.4.12. Nasal
Sprays
18.9.3.4.13. Dental
Products
18.9.3.4.14. Pessaries
18.9.3.4.15. Others
18.9.3.5. Egypt
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
18.9.3.5.1. Phase
I Trials
18.9.3.5.2. Phase
II/III trials
18.9.3.5.3. Others
18.9.3.6. Egypt
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
18.9.3.6.1. Gastrointestinal
Disorders and Food Allergies
18.9.3.6.2. Cardiovascular
Diseases
18.9.3.6.3. Metabolic
18.9.3.6.4. Autoimmune
and Neurological Disorders
18.9.3.6.5. Diabetes
18.9.3.6.6. Cancer
18.9.3.6.7. Infectious
Diseases
18.9.3.6.8. Others
18.9.3.7. Egypt
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
18.9.3.7.1. Cell
Bank Preservation
18.9.3.7.2. Inoculum/Seed
Optimization
18.9.3.7.3. Media
Optimization
18.9.3.7.4. Formulation
18.9.3.7.5. Fermentation
Development
18.9.3.7.6. Harvest
Development
18.9.3.7.7. Lyophilization
Development
18.9.3.7.8. Analytical
Method Development
18.9.3.7.9. Process
Scale-Up
18.9.3.7.10. Liquid
Filling Services
18.9.3.7.11. Custom
Packaging Services
18.9.3.7.12. Others
18.9.4. Kuwait
18.9.4.1. Kuwait
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
18.9.4.1.1. Pharma
Customers
18.9.4.1.2. Biotech
Customers
18.9.4.1.3. Others
18.9.4.2. Kuwait
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
18.9.4.2.1. Active
Pharmaceutical Ingredients
18.9.4.2.2. Finished
Drugs
18.9.4.3. Kuwait
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
18.9.4.3.1. Aerobic
18.9.4.3.2. Anaerobic
18.9.4.4. Kuwait
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
18.9.4.4.1. Immediate
Release and Controlled Release Tablets
18.9.4.4.2. Multilayer
Tablets
18.9.4.4.3. Immediate
Release Capsules
18.9.4.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
18.9.4.4.5. Liquid
and Semi-solid Filled Capsules
18.9.4.4.6. Fast
Dispersible Tablets
18.9.4.4.7. Coating
of Tablets, Capsules and Pellets
18.9.4.4.8. Micro-encapsulation
Using Spray Drying
18.9.4.4.9. Oral
Liquids and Suspensions
18.9.4.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
18.9.4.4.11. Buccal
Delivery
18.9.4.4.12. Nasal
Sprays
18.9.4.4.13. Dental
Products
18.9.4.4.14. Pessaries
18.9.4.4.15. Others
18.9.4.5. Kuwait
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
18.9.4.5.1. Phase
I Trials
18.9.4.5.2. Phase
II/III trials
18.9.4.5.3. Others
18.9.4.6. Kuwait
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
18.9.4.6.1. Gastrointestinal
Disorders and Food Allergies
18.9.4.6.2. Cardiovascular
Diseases
18.9.4.6.3. Metabolic
18.9.4.6.4. Autoimmune
and Neurological Disorders
18.9.4.6.5. Diabetes
18.9.4.6.6. Cancer
18.9.4.6.7. Infectious
Diseases
18.9.4.6.8. Others
18.9.4.7. Kuwait
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
18.9.4.7.1. Cell
Bank Preservation
18.9.4.7.2. Inoculum/Seed
Optimization
18.9.4.7.3. Media
Optimization
18.9.4.7.4. Formulation
18.9.4.7.5. Fermentation
Development
18.9.4.7.6. Harvest
Development
18.9.4.7.7. Lyophilization
Development
18.9.4.7.8. Analytical
Method Development
18.9.4.7.9. Process
Scale-Up
18.9.4.7.10. Liquid
Filling Services
18.9.4.7.11. Custom
Packaging Services
18.9.4.7.12. Others
18.9.5. South
Africa
18.9.5.1. South
Africa Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
18.9.5.1.1. Pharma
Customers
18.9.5.1.2. Biotech
Customers
18.9.5.1.3. Others
18.9.5.2. South
Africa Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
18.9.5.2.1. Active
Pharmaceutical Ingredients
18.9.5.2.2. Finished
Drugs
18.9.5.3. South
Africa Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
18.9.5.3.1. Aerobic
18.9.5.3.2. Anaerobic
18.9.5.4. South
Africa Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
18.9.5.4.1. Immediate
Release and Controlled Release Tablets
18.9.5.4.2. Multilayer
Tablets
18.9.5.4.3. Immediate
Release Capsules
18.9.5.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
18.9.5.4.5. Liquid
and Semi-solid Filled Capsules
18.9.5.4.6. Fast
Dispersible Tablets
18.9.5.4.7. Coating
of Tablets, Capsules and Pellets
18.9.5.4.8. Micro-encapsulation
Using Spray Drying
18.9.5.4.9. Oral
Liquids and Suspensions
18.9.5.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
18.9.5.4.11. Buccal
Delivery
18.9.5.4.12. Nasal
Sprays
18.9.5.4.13. Dental
Products
18.9.5.4.14. Pessaries
18.9.5.4.15. Others
18.9.5.5. South
Africa Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
18.9.5.5.1. Phase
I Trials
18.9.5.5.2. Phase
II/III trials
18.9.5.5.3. Others
18.9.5.6. South
Africa Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
18.9.5.6.1. Gastrointestinal
Disorders and Food Allergies
18.9.5.6.2. Cardiovascular
Diseases
18.9.5.6.3. Metabolic
18.9.5.6.4. Autoimmune
and Neurological Disorders
18.9.5.6.5. Diabetes
18.9.5.6.6. Cancer
18.9.5.6.7. Infectious
Diseases
18.9.5.6.8. Others
18.9.5.7. South
Africa Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
18.9.5.7.1. Cell
Bank Preservation
18.9.5.7.2. Inoculum/Seed
Optimization
18.9.5.7.3. Media
Optimization
18.9.5.7.4. Formulation
18.9.5.7.5. Fermentation
Development
18.9.5.7.6. Harvest
Development
18.9.5.7.7. Lyophilization
Development
18.9.5.7.8. Analytical
Method Development
18.9.5.7.9. Process
Scale-Up
18.9.5.7.10. Liquid
Filling Services
18.9.5.7.11. Custom
Packaging Services
18.9.5.7.12. Others
18.9.6. Rest of
Middle East & Africa
18.9.6.1. Rest
of Middle East & Africa Live Biotherapeutic Products and Microbiome
Contract Manufacturing Market Revenue (US$ Mn) and Forecasts, By End User
18.9.6.1.1. Pharma
Customers
18.9.6.1.2. Biotech
Customers
18.9.6.1.3. Others
18.9.6.2. Rest
of Middle East & Africa Live Biotherapeutic Products and Microbiome
Contract Manufacturing Market Revenue (US$ Mn) and Forecasts, By Product
18.9.6.2.1. Active
Pharmaceutical Ingredients
18.9.6.2.2. Finished
Drugs
18.9.6.3. Rest
of Middle East & Africa Live Biotherapeutic Products and Microbiome
Contract Manufacturing Market Revenue (US$ Mn) and Forecasts, By Type of
Fermentation
18.9.6.3.1. Aerobic
18.9.6.3.2. Anaerobic
18.9.6.4. Rest
of Middle East & Africa Live Biotherapeutic Products and Microbiome
Contract Manufacturing Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
18.9.6.4.1. Immediate
Release and Controlled Release Tablets
18.9.6.4.2. Multilayer
Tablets
18.9.6.4.3. Immediate
Release Capsules
18.9.6.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
18.9.6.4.5. Liquid
and Semi-solid Filled Capsules
18.9.6.4.6. Fast
Dispersible Tablets
18.9.6.4.7. Coating
of Tablets, Capsules and Pellets
18.9.6.4.8. Micro-encapsulation
Using Spray Drying
18.9.6.4.9. Oral
Liquids and Suspensions
18.9.6.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
18.9.6.4.11. Buccal
Delivery
18.9.6.4.12. Nasal
Sprays
18.9.6.4.13. Dental
Products
18.9.6.4.14. Pessaries
18.9.6.4.15. Others
18.9.6.5. Rest
of Middle East & Africa Live Biotherapeutic Products and Microbiome
Contract Manufacturing Market Revenue (US$ Mn) and Forecasts, By Clinical
Phases
18.9.6.5.1. Phase
I Trials
18.9.6.5.2. Phase
II/III trials
18.9.6.5.3. Others
18.9.6.6. Rest of
Middle East & Africa Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Disease Indication
18.9.6.6.1. Gastrointestinal
Disorders and Food Allergies
18.9.6.6.2. Cardiovascular
Diseases
18.9.6.6.3. Metabolic
18.9.6.6.4. Autoimmune
and Neurological Disorders
18.9.6.6.5. Diabetes
18.9.6.6.6. Cancer
18.9.6.6.7. Infectious
Diseases
18.9.6.6.8. Others
18.9.6.7. Rest
of Middle East & Africa Live Biotherapeutic Products and Microbiome
Contract Manufacturing Market Revenue (US$ Mn) and Forecasts, By Services
18.9.6.7.1. Cell
Bank Preservation
18.9.6.7.2. Inoculum/Seed
Optimization
18.9.6.7.3. Media
Optimization
18.9.6.7.4. Formulation
18.9.6.7.5. Fermentation
Development
18.9.6.7.6. Harvest
Development
18.9.6.7.7. Lyophilization
Development
18.9.6.7.8. Analytical
Method Development
18.9.6.7.9. Process
Scale-Up
18.9.6.7.10. Liquid
Filling Services
18.9.6.7.11. Custom
Packaging Services
18.9.6.7.12. Others
18.10. Key
Segment for Channeling Investments
18.10.1. By
Country
18.10.2. By End
User
18.10.3. By
Product
18.10.4. By
Type of Fermentation
18.10.5. By
Dosage Forms
18.10.6. By
Clinical Phases
18.10.7. By
Disease Indication
18.10.8. By
Services
19. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Analysis and Forecasts, 2022 - 2030
19.1. Overview
19.1.1. Latin America
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn)
19.2. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By End User
19.2.1. Pharma
Customers
19.2.2. Biotech
Customers
19.2.3. Others
19.3. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Product
19.3.1. Active
Pharmaceutical Ingredients
19.3.2. Finished
Drugs
19.4. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
19.4.1. Aerobic
19.4.2. Anaerobic
19.5. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
19.5.1. Immediate
Release and Controlled Release Tablets
19.5.2. Multilayer
Tablets
19.5.3. Immediate
Release Capsules
19.5.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
19.5.5. Liquid
and Semi-solid Filled Capsules
19.5.6. Fast
Dispersible Tablets
19.5.7. Coating
of Tablets, Capsules and Pellets
19.5.8. Micro-encapsulation
Using Spray Drying
19.5.9. Oral
Liquids and Suspensions
19.5.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
19.5.11. Buccal
Delivery
19.5.12. Nasal
Sprays
19.5.13. Dental
Products
19.5.14. Pessaries
19.5.15. Others
19.6. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
19.6.1. Phase I
Trials
19.6.2. Phase
II/III trials
19.6.3. Others
19.7. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
19.7.1. Gastrointestinal
Disorders and Food Allergies
19.7.2. Cardiovascular
Diseases
19.7.3. Metabolic
19.7.4. Autoimmune
and Neurological Disorders
19.7.5. Diabetes
19.7.6. Cancer
19.7.7. Infectious
Diseases
19.7.8. Others
19.8. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Services
19.8.1. Cell
Bank Preservation
19.8.2. Inoculum/Seed
Optimization
19.8.3. Media
Optimization
19.8.4. Formulation
19.8.5. Fermentation
Development
19.8.6. Harvest
Development
19.8.7. Lyophilization
Development
19.8.8. Analytical
Method Development
19.8.9. Process
Scale-Up
19.8.10. Liquid
Filling Services
19.8.11. Custom
Packaging Services
19.8.12. Others
19.9. Latin
America Live Biotherapeutic Products and Microbiome Contract Manufacturing
Market Revenue (US$ Mn) and Forecasts, By Country
19.9.1. Brazil
19.9.1.1. Brazil
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
19.9.1.1.1. Pharma
Customers
19.9.1.1.2. Biotech
Customers
19.9.1.1.3. Others
19.9.1.2. Brazil
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
19.9.1.2.1. Active
Pharmaceutical Ingredients
19.9.1.2.2. Finished
Drugs
19.9.1.3. Brazil
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
19.9.1.3.1. Aerobic
19.9.1.3.2. Anaerobic
19.9.1.4. Brazil
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
19.9.1.4.1. Immediate
Release and Controlled Release Tablets
19.9.1.4.2. Multilayer
Tablets
19.9.1.4.3. Immediate
Release Capsules
19.9.1.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
19.9.1.4.5. Liquid
and Semi-solid Filled Capsules
19.9.1.4.6. Fast
Dispersible Tablets
19.9.1.4.7. Coating
of Tablets, Capsules and Pellets
19.9.1.4.8. Micro-encapsulation
Using Spray Drying
19.9.1.4.9. Oral
Liquids and Suspensions
19.9.1.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
19.9.1.4.11. Buccal
Delivery
19.9.1.4.12. Nasal
Sprays
19.9.1.4.13. Dental
Products
19.9.1.4.14. Pessaries
19.9.1.4.15. Others
19.9.1.5. Brazil
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
19.9.1.5.1. Phase
I Trials
19.9.1.5.2. Phase
II/III trials
19.9.1.5.3. Others
19.9.1.6. Brazil
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
19.9.1.6.1. Gastrointestinal
Disorders and Food Allergies
19.9.1.6.2. Cardiovascular
Diseases
19.9.1.6.3. Metabolic
19.9.1.6.4. Autoimmune
and Neurological Disorders
19.9.1.6.5. Diabetes
19.9.1.6.6. Cancer
19.9.1.6.7. Infectious
Diseases
19.9.1.6.8. Others
19.9.1.7. Brazil
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
19.9.1.7.1. Cell
Bank Preservation
19.9.1.7.2. Inoculum/Seed
Optimization
19.9.1.7.3. Media
Optimization
19.9.1.7.4. Formulation
19.9.1.7.5. Fermentation
Development
19.9.1.7.6. Harvest
Development
19.9.1.7.7. Lyophilization
Development
19.9.1.7.8. Analytical
Method Development
19.9.1.7.9. Process
Scale-Up
19.9.1.7.10. Liquid
Filling Services
19.9.1.7.11. Custom
Packaging Services
19.9.1.7.12. Others
19.9.2. Argentina
19.9.2.1. Argentina
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By End User
19.9.2.1.1. Pharma
Customers
19.9.2.1.2. Biotech
Customers
19.9.2.1.3. Others
19.9.2.2. Argentina
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Product
19.9.2.2.1. Active
Pharmaceutical Ingredients
19.9.2.2.2. Finished
Drugs
19.9.2.3. Argentina
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Type of Fermentation
19.9.2.3.1. Aerobic
19.9.2.3.2. Anaerobic
19.9.2.4. Argentina
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Dosage Forms
19.9.2.4.1. Immediate
Release and Controlled Release Tablets
19.9.2.4.2. Multilayer
Tablets
19.9.2.4.3. Immediate
Release Capsules
19.9.2.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
19.9.2.4.5. Liquid
and Semi-solid Filled Capsules
19.9.2.4.6. Fast
Dispersible Tablets
19.9.2.4.7. Coating
of Tablets, Capsules and Pellets
19.9.2.4.8. Micro-encapsulation
Using Spray Drying
19.9.2.4.9. Oral
Liquids and Suspensions
19.9.2.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
19.9.2.4.11. Buccal
Delivery
19.9.2.4.12. Nasal
Sprays
19.9.2.4.13. Dental
Products
19.9.2.4.14. Pessaries
19.9.2.4.15. Others
19.9.2.5. Argentina
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
19.9.2.5.1. Phase
I Trials
19.9.2.5.2. Phase
II/III trials
19.9.2.5.3. Others
19.9.2.6. Argentina
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
19.9.2.6.1. Gastrointestinal
Disorders and Food Allergies
19.9.2.6.2. Cardiovascular
Diseases
19.9.2.6.3. Metabolic
19.9.2.6.4. Autoimmune
and Neurological Disorders
19.9.2.6.5. Diabetes
19.9.2.6.6. Cancer
19.9.2.6.7. Infectious
Diseases
19.9.2.6.8. Others
19.9.2.7. Argentina
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
Revenue (US$ Mn) and Forecasts, By Services
19.9.2.7.1. Cell
Bank Preservation
19.9.2.7.2. Inoculum/Seed
Optimization
19.9.2.7.3. Media
Optimization
19.9.2.7.4. Formulation
19.9.2.7.5. Fermentation
Development
19.9.2.7.6. Harvest
Development
19.9.2.7.7. Lyophilization
Development
19.9.2.7.8. Analytical
Method Development
19.9.2.7.9. Process
Scale-Up
19.9.2.7.10. Liquid
Filling Services
19.9.2.7.11. Custom
Packaging Services
19.9.2.7.12. Others
19.9.3. Rest of
Latin America
19.9.3.1. Rest
of Latin America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By End User
19.9.3.1.1. Pharma
Customers
19.9.3.1.2. Biotech
Customers
19.9.3.1.3. Others
19.9.3.2. Rest
of Latin America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Product
19.9.3.2.1. Active
Pharmaceutical Ingredients
19.9.3.2.2. Finished
Drugs
19.9.3.3. Rest
of Latin America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Type of Fermentation
19.9.3.3.1. Aerobic
19.9.3.3.2. Anaerobic
19.9.3.4. Rest
of Latin America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Dosage Forms
19.9.3.4.1. Immediate
Release and Controlled Release Tablets
19.9.3.4.2. Multilayer
Tablets
19.9.3.4.3. Immediate
Release Capsules
19.9.3.4.4. Oral
Multiparticulates such as Beads, Pellets and Mini-tablets
19.9.3.4.5. Liquid
and Semi-solid Filled Capsules
19.9.3.4.6. Fast
Dispersible Tablets
19.9.3.4.7. Coating
of Tablets, Capsules and Pellets
19.9.3.4.8. Micro-encapsulation
Using Spray Drying
19.9.3.4.9. Oral
Liquids and Suspensions
19.9.3.4.10. Liquids
and Semi-solids for Topical Delivery, such as Creams, Ointments, Lotions and
Gels
19.9.3.4.11. Buccal
Delivery
19.9.3.4.12. Nasal
Sprays
19.9.3.4.13. Dental
Products
19.9.3.4.14. Pessaries
19.9.3.4.15. Others
19.9.3.5. Rest
of Latin America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
19.9.3.5.1. Phase
I Trials
19.9.3.5.2. Phase
II/III trials
19.9.3.5.3. Others
19.9.3.6. Rest
of Latin America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Disease Indication
19.9.3.6.1. Gastrointestinal
Disorders and Food Allergies
19.9.3.6.2. Cardiovascular
Diseases
19.9.3.6.3. Metabolic
19.9.3.6.4. Autoimmune
and Neurological Disorders
19.9.3.6.5. Diabetes
19.9.3.6.6. Cancer
19.9.3.6.7. Infectious
Diseases
19.9.3.6.8. Others
19.9.3.7. Rest
of Latin America Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market Revenue (US$ Mn) and Forecasts, By Services
19.9.3.7.1. Cell
Bank Preservation
19.9.3.7.2. Inoculum/Seed
Optimization
19.9.3.7.3. Media
Optimization
19.9.3.7.4. Formulation
19.9.3.7.5. Fermentation
Development
19.9.3.7.6. Harvest
Development
19.9.3.7.7. Lyophilization
Development
19.9.3.7.8. Analytical
Method Development
19.9.3.7.9. Process
Scale-Up
19.9.3.7.10. Liquid
Filling Services
19.9.3.7.11. Custom
Packaging Services
19.9.3.7.12. Others
19.10. Key
Segment for Channeling Investments
19.10.1. By
Country
19.10.2. By End
User
19.10.3. By
Product
19.10.4. By
Type of Fermentation
19.10.5. By
Dosage Forms
19.10.6. By
Clinical Phases
19.10.7. By
Disease Indication
19.10.8. By
Services
20. Competitive
Benchmarking
20.1. Market
Share Analysis, 2021
20.2. Global
Presence and Growth Strategies
20.2.1. Mergers
and Acquisitions
20.2.2. Product
Launches
20.2.3. Investments
Trends
20.2.4. R&D
Initiatives
21. Player
Profiles
21.1. 3P
Biopharmaceuticals
21.1.1. Company
Details
21.1.2. Company
Overview
21.1.3. Product
Offerings
21.1.4. Key
Developments
21.1.5. Financial
Analysis
21.1.6. SWOT
Analysis
21.1.7. Business
Strategies
21.2. BIOSE
INDUSTRIES
21.2.1. Company
Details
21.2.2. Company
Overview
21.2.3. Product
Offerings
21.2.4. Key
Developments
21.2.5. Financial
Analysis
21.2.6. SWOT
Analysis
21.2.7. Business
Strategies
21.3. BJP Laboratories
21.3.1. Company
Details
21.3.2. Company
Overview
21.3.3. Product
Offerings
21.3.4. Key
Developments
21.3.5. Financial
Analysis
21.3.6. SWOT
Analysis
21.3.7. Business
Strategies
21.4. Cerbios-Pharma
SA
21.4.1. Company
Details
21.4.2. Company
Overview
21.4.3. Product
Offerings
21.4.4. Key
Developments
21.4.5. Financial
Analysis
21.4.6. SWOT
Analysis
21.4.7. Business
Strategies
21.5. Capsugel
21.5.1. Company
Details
21.5.2. Company
Overview
21.5.3. Product
Offerings
21.5.4. Key
Developments
21.5.5. Financial
Analysis
21.5.6. SWOT
Analysis
21.5.7. Business
Strategies
21.6. Cobra
Biologics Limited
21.6.1. Company
Details
21.6.2. Company
Overview
21.6.3. Product
Offerings
21.6.4. Key
Developments
21.6.5. Financial
Analysis
21.6.6. SWOT
Analysis
21.6.7. Business
Strategies
21.7. Inpac
Probiotics
21.7.1. Company
Details
21.7.2. Company
Overview
21.7.3. Product
Offerings
21.7.4. Key
Developments
21.7.5. Financial
Analysis
21.7.6. SWOT
Analysis
21.7.7. Business
Strategies
21.8. Quay
Pharma
21.8.1. Company
Details
21.8.2. Company
Overview
21.8.3. Product
Offerings
21.8.4. Key
Developments
21.8.5. Financial
Analysis
21.8.6. SWOT
Analysis
21.8.7. Business
Strategies
21.9. List
Biological Labs, Inc
21.9.1. Company
Details
21.9.2. Company
Overview
21.9.3. Product
Offerings
21.9.4. Key
Developments
21.9.5. Financial
Analysis
21.9.6. SWOT
Analysis
21.9.7. Business
Strategies
21.10. Lonza
21.10.1. Company
Details
21.10.2. Company
Overview
21.10.3. Product
Offerings
21.10.4. Key
Developments
21.10.5. Financial
Analysis
21.10.6. SWOT
Analysis
21.10.7. Business
Strategies
21.11. Arranta
Bio
21.11.1. Company
Details
21.11.2. Company
Overview
21.11.3. Product
Offerings
21.11.4. Key
Developments
21.11.5. Financial
Analysis
21.11.6. SWOT
Analysis
21.11.7. Business
Strategies
21.12. Other
Market Participants
22. Key
Findings
Note: This ToC
is tentative and can be changed according to the research study conducted
during the course of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.